<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        125-186-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LOMAX 400MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LOMEFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C , Protect from light and moisture
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        61.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Treatment</u></strong></p><p><strong>Lomax</strong> (lomefloxacin HCl) film-coated tablets are indicated for the treatment of adults in the conditions listed below:</p><p>&sect; <strong>Lower respiratory tract</strong>:</p><p>-&nbsp; Acute Bacterial Exacerbation of Chronic Bronchitis</p><p>&sect; <strong>Urinary tract: </strong></p><p>-&nbsp; Uncomplicated Urinary Tract Infections&nbsp;(cystitis)</p><p>-&nbsp; Complicated Urinary Tract Infection</p><p><strong><u>Prevention / prophylaxis</u></strong></p><p><strong>Lomax</strong> is indicated preoperatively for the prevention of infection in the following situations:</p><p>&sect; Transrectal prostate biopsy: to reduce the incidence of urinary tract infection, in the early and late postoperative periods (3&ndash;5 days and 3&ndash;4 weeks post-surgery).</p><p>&sect; Transurethral surgical procedures: to reduce the incidence of urinary tract infection in the early postoperative period (3&ndash;5 days post-surgery).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lomax:</strong></p><p>&sect; If you are allergic to the active substance lomefloxacin, any of the other ingredients of this medicine (listed in section 6.), or If you have a history of hypersensitivity to any other quinolone antibiotics.</p><p><strong>Fluoroquinolone antibiotics (such as Lomefloxacin) should&nbsp;not&nbsp;be used:</strong></p><p>&sect; To treat infections that might get better without treatment or are not severe (such as throat infections);</p><p>&sect; To treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis;</p><p>&sect; For preventing traveller&rsquo;s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder);</p><p>&sect; To treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used.</p><p>Fluoroquinolones should generally be&nbsp;<strong>avoided</strong>&nbsp;in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.</p><p>Fluoroquinolones should be used&nbsp;<strong>with special caution</strong>&nbsp;in the elderly, patients with kidney disease and those who have had an organ transplantation because these patients are at a higher risk of tendon injury. Since the use of a corticosteroid with a Fluoroquinolone also increases this risk, combined use of these medicines should be avoided.</p><p><strong>Warnings and precautions </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Fluoroquinolone antibiotics may cause the following: </u></strong></p><p>&sect; <strong>Significant decreases in blood sugar</strong>: the low blood sugar levels can result in serious problems, including coma, particularly in older people and patients with diabetes who are taking medicines to reduce blood sugar.</p><p>You should tell your doctor if you are taking a diabetes medicine when he/she is considering prescribing an antibiotic, and also if you have low blood sugar or symptoms of it while taking a fluoroquinolone. For patients with diabetes, your doctor may ask you to check your blood sugar more often while taking a fluoroquinolone.</p><p>Early signs and symptoms of low blood sugar include: confusion, pounding heart or very fast pulse, dizziness, pale skin, feeling shaky, sweating, unusual hunger, trembling, headaches, weakness, irritability and unusual anxiety.</p><p>Discuss with your doctor how to treat yourself if you suspect low blood sugar.</p><p>Symptoms of low blood sugar can progress and become life-threatening, so seek medical help immediately or go to emergency at the nearest hospital if you experience more serious symptoms, including confusion, inability to complete routine tasks, blurred vision, seizures or loss of consciousness.</p><p>&sect; <strong>Certain mental health side effects</strong>:&nbsp; disturbances in attention, disorientation, agitation, nervousness, memory impairment, and serious disturbances in mental abilities called delirium.</p><p>You should tell your doctor immediately if you notice any changes in your mood, behaviour or thinking.</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>Talk to your doctor before taking Lomax:</strong></p><p>&sect; If you are pregnant or are breast-feeding.</p><p>&sect; If <em>you</em> are under 18 years of age.</p><p>&sect; If you suffer from epilepsy or a condition which makes you likely to have convulsions talk to your doctor before taking <strong>Lomax</strong>.</p><p>&sect; If you have or have ever had any mental health problems, consult your doctor before taking <strong>Lomax</strong>.</p><p>&sect; Quinolones may cause central nervous system (CNS) stimulation, which may lead to tremors, restlessness, light headedness, confusion, and hallucinations. If any of these reactions occurs in patients receiving <strong>Lomax</strong>, it should be discontinued and appropriate measures instituted.</p><p>&sect; <strong>Lomax</strong> can change your heart&rsquo;s ECG (QT interval prolongation/torsades de pointes), especially if you are female, if you are elderly (over 60), if you suffer from cardiac disease or If you are taking multiple medications.</p><p>&sect; You may experience symptoms of nerve damage (Peripheral neuropathy) such as pain, burning, tingling, numbness, and/or weakness, especially in the feet and legs or hands and arms, inform your doctor immediately prior to continuing treatment with <strong>Lomax.</strong></p><p>&sect; <strong>Lomax</strong> may cause pain and inflammation of your tendons. The risk of inflammation and rupture of tendons is increased if you are elderly or if you are also taking corticosteroids. At the first sign of any pain or inflammation you should stop taking <strong>Lomax</strong>, rest the affected limb(s) and consult your doctor immediately.<strong> </strong>Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture. Tendon rupture can occur during or after therapy with quinolones, including lomefloxacin.</p><p>&sect; You may develop diarrhoea whilst or after taking antibiotics including <strong>Lomax</strong> (Pseudomembranous colitis has been reported with nearly all antibacterial agents, including lomefloxacin and may range from mild to life-threatening in severity.).<strong> </strong>If this becomes severe or persistent or you notice that your stool contains blood or mucus you should stop taking <strong>Lomax</strong> immediately and consult your doctor. You should not take medicines that stop or slow down bowel movement.</p><p>&sect; You may experience a serious and occasionally fatal hypersensitivity (anaphylactoid or anaphylactic) reactions even <em>with</em> the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial oedema, dyspnoea, urticaria, or itching. If so, stop taking <strong>Lomax</strong> and seek medical advice immediately.</p><p>&sect; <em>If</em> you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</p><p>&sect; <em>If</em> you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</p><p>&sect; If you have been diagnosed with leaking heart valves (heart valve regurgitation).</p><p>&sect; If you have a family history of aortic aneurysm or aortic dissection or congenital heart valve disease, or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Sj&ouml;gren&rsquo;s syndrome [an inflammatory autoimmune disease], or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&acute;s disease, high blood pressure, or known atherosclerosis, rheumatoid arthritis [a disease of the joints] or endocarditis [an infection of the heart]).</p><p>&sect; If you suffer from impairment of renal function (Cl &lt; 40 mL/min/1.73m<sup>2</sup>).</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children and adolescents under the age of 18 because efficacy and safety have not been established for this age group.</p><p><strong>While taking Lomax </strong></p><p>Tell your doctor immediately, if any of the following occurs <strong>while taking Lomax</strong>. Your doctor will decide whether treatment with <strong>Lomax</strong> needs to be stopped.</p><p>&sect; <strong>Prolonged, disabling and potentially irreversible serious side effects</strong>. Fluoroquinolone/ quinolone antibacterial medicines, including lomefloxacin, have been associated with very rare but serious side effects, some of them being long lasting (continuing months or years), disabling or potentially irreversible. This includes tendon, muscle and joint pain of the upper and lower limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, numbness or burning (paraesthesia), sensory disorders including impairment of vision, taste and smell, and hearing, depression, memory impairment, severe fatigue, and severe sleep disorders. If you experience any of these side effects after taking lomefloxacin, contact your doctor immediately prior to continuing treatment. You and your doctor will decide on continuing the treatment considering also an antibiotic from another class.&nbsp;</p><p>&sect; If you feel <strong>sudden, severe pain in your abdomen, chest or back, which can be symptoms of aortic aneurysm and dissection</strong>, go immediately to an emergency room. Your risk may be increased if you are being treated with systemic corticosteroids.</p><p>&sect; If you start experiencing a <strong>rapid onset of shortness of breath</strong>, especially when you lie down flat in your bed, or you notice <strong>swelling of your ankles, feet or abdomen, or a new onset of heart palpitations </strong>(sensation of rapid or irregular heartbeat), you should inform a doctor immediately.</p><p><strong>Other medicines and Lomax</strong></p><p>Tell your doctor or pharmacist about any other medicines that you are taking, took recently or might take.</p><p><u>Before taking <strong>Lomax</strong>, tell your doctor or pharmacist if you are taking any of the following:</u></p><p>&sect; Any medicine containing magnesium or aluminium (such as antacids for indigestion), or didanosine or any medicine containing sucralfate (to treat stomach disorders) may reduce the absorption of lomefloxacin; Therefore, these medications should be taken at least 4 hours before or 2 hours after administration of lomefloxacin.</p><p>&sect; <em>Probenecid, may reduce the renal elimination of lomefloxacin when given concomitantly.</em></p><p>&sect; <em>The oral anticoagulant effect (such as warfarin or its derivatives) may be enhanced when lomefloxacin</em> <em>is given concomitantly. </em>It may be necessary for your doctor to monitor your blood clotting time.</p><p><u>Take caution while taking any of the following medicines:&nbsp;&nbsp; </u></p><p>&sect; <em>Cyclosporine. Since other quinolones may elevate serum cyclosporine levels, cyclosporine concentrations should be monitored when used concurrently with lomefloxacin. </em></p><p>&sect; <em>Caffeine. Since other quinolones may interfere with the metabolism of caffeine resulting in a reduced clearance, increasing thereby its half-life and the risk of caffeine-related CNS stimulation; concurrent use is better to be avoided. </em></p><p>&sect; <em>Cimetidine. It has been demonstrated to interfere with the elimination of other quinolones.</em></p><p><em><u>Tell your doctor if you are taking any of the following </u></em><u>medicines<em>: </em></u></p><p>&sect; Phenytoin</p><p>&sect; Theophylline.</p><p>&sect; <em>Omeprazole</em></p><p>&sect; <em>Terfenadine</em></p><p><strong>Exposure to sunlight </strong></p><p>Quinolone antibiotics may make your skin become more sensitive to sunlight or UV light. You should avoid prolonged exposure to sunlight or strong sunlight and should not use a sunbed or any other UV lamp while taking <strong>Lomax</strong>. The risk of developing phototoxicity from sunlight may reduce by taking the daily dose of&nbsp; <strong>Lomax</strong> at least 12 hours before exposure to the sun (e.g. in the evening). Please discontinue <strong>Lomax</strong> therapy at the first signs or symptoms of phototoxicity reaction such as a sensation of skin burning, redness, swelling, blisters, rash, itching, or dermatitis.</p><p><strong>Taking Lomax</strong> <strong>with food and drink</strong></p><p><strong>Lomax</strong> can be taken with or without food.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>Do not take <strong>Lomax</strong> if you are pregnant or breast-feeding.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Animal studies do not indicate that your fertility will be impaired by taking this medicine.</p><p><strong>Driving and using machines</strong></p><p><strong>Lomax</strong> may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you may faint for a short period. If you are affected do not drive or operate machinery.</p><p><strong>Important information of some ingredients of lomax </strong></p><p><strong>Lomax</strong> contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor<strong> </strong>before taking <strong>Lomax</strong>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong><u>Treatment</u></strong></p><p>Patients with normal renal function</p><p>The recommended daily dose of <strong>Lomax</strong> is described in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Unit Dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td><td style="vertical-align:top"><p><strong>Daily Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial exacerbation</p><p>of chronic bronchitis</p></td><td style="vertical-align:top"><p>400mg</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>10 days</p></td><td style="vertical-align:top"><p>400mg</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis in</p><p>females caused by <em>E coli</em></p></td><td style="vertical-align:top"><p>400mg</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>400mg</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis</p><p>caused by <em>K pneumoniae, P</em></p><p><em>mirabilis, </em>or <em>S Saprophyticus</em></p></td><td style="vertical-align:top"><p>400mg</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>10 days</p></td><td style="vertical-align:top"><p>400mg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated UTI</p></td><td style="vertical-align:top"><p>400mg</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>14 days</p></td><td style="vertical-align:top"><p>400mg</p></td></tr></tbody></table><p><strong>Elderly patients</strong></p><p>No dosage adjustment is needed for elderly patients with normal renal function (Cl &ge; 40 mL/min/1.73m<sup>2</sup>).</p><p><strong>If you take more </strong><strong>Lomax</strong> <strong>than you should</strong></p><p>If you take more than the prescribed dose, get medical help immediately. Try to take any remaining tablets, the packaging or this leaflet with you to show the doctor or pharmacist what you have taken.</p><p><strong>If you forget to take </strong><strong>Lomax</strong></p><p>If you forget to take your tablet you should take it as soon as you remember on the same day. If you do not remember on the same day, take your normal dose on the next day. Do not take a double dose to make up for a forgotten dose.</p><p>If you are unsure about what to do ask your doctor or pharmacist.</p><p><strong>If you stop taking </strong><strong>Lomax</strong></p><p>If you stop taking this medicine too soon your infection may not be completely cured. Talk to your doctor if you wish to stop taking your tablets before the end of the course of treatment.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Lomax</strong> can cause side effects, although not everybody gets them.</p><p>In clinical trials, most of the adverse events reported were mild to moderate in severity and transient in nature. During these clinical investigations, 5,623 patients received lomefloxacin. In 2.2% of the patients, lomefloxacin was discontinued because of adverse events, primarily involving the gastrointestinal system (0.7%), skin (0.7%), or CNS (0.5%).</p><p><strong>Adverse clinical events</strong></p><p>The events with the highest incidence (&ge; 1%) in patients, regardless of relationship to drug, were headache (3.6%), nausea (3.5%), photosensitivity (2.3%), dizziness (2.1%), diarrhoea (1.4%), and abdominal pain (1.2%).</p><p>Additional clinical events reported in &lt; 1% of patients treated with Lomefloxacin, regardless of relationship to drug, are listed below:</p><p>&sect; <em>Autonomic: </em>increased sweating, dry mouth, flushing, syncope.</p><p>&sect; <em>Body as a whole*: </em>fatigue, back pain, malaise, asthenia, chest pain, face oedema, hot flashes, influenza-like symptoms, oedema, chills, allergic reaction, anaphylactoid reaction, decreased heat tolerance.</p><p>&sect; <em>Cardiovascular**: </em>tachycardia, hypertension, hypotension, myocardial infarction, angina pectoris, cardiac failure, bradycardia, arrhythmia, phlebitis, pulmonary embolism, extrasystoles, cerebrovascular disorder, cyanosis, cardiomyopathy.</p><p>&sect; <em>Central and peripheral nervous system*: </em>tremor, vertigo, paresthesias, twitching, hypertonia, convulsions, hyperkinesia, coma.</p><p>&sect; <em>Gastrointestinal: </em>dyspepsia, vomiting, flatulence, constipation, gastrointestinal bleeding, dysphagia, stomatitis, tongue discoloration, gastrointestinal inflammation.</p><p>&sect; <em>Hearing*: </em>earache, tinnitus.</p><p>&sect; <em>Hematologic: </em>purpura, lymphadenopathy, thrombocythemia, anaemia, thrombocytopenia, increased fibrinolysis.</p><p>&sect; <em>Hepatic: </em>abnormal liver function.</p><p>&sect; <em>Metabolic: </em>thirst, hyperglycaemia, hypoglycaemia, gout.</p><p>&sect; <em>Musculoskeletal*: </em>arthralgia, myalgia, leg cramps.</p><p>&sect; <em>Ophthalmologic*: </em>abnormal vision, conjunctivitis, photophobia, eye pain, abnormal lacrimation.</p><p>&sect; <em>Psychiatric*: </em>insomnia, nervousness, somnolence, anorexia, depression, confusion, agitation, increased appetite, depersonalization, paranoid reaction, anxiety, paroniria, abnormal thinking, concentration impairment.</p><p>&sect; <em>Reproductive system: </em>Female: vaginal moniliasis, vaginitis, leukorrhea, menstrual disorder, perineal pain, intermenstrual bleeding. Male: epididymitis, orchitis.</p><p>&sect; <em>Resistance mechanism: </em>viral infection, moniliasis, fungal infection.</p><p>&sect; <em>Respiratory: </em>respiratory infection, rhinitis, pharyngitis, dyspnoea, cough, epistaxis, bronchospasm, respiratory disorder, increased sputum, stridor, respiratory depression.</p><p>&sect; <em>Skin/Allergic: </em>pruritus, rash, urticaria, skin exfoliation, bullous eruption, eczema, skin disorder, acne, skin discoloration, skin ulceration, angioedema. (See also <em>Body as a whole.</em>)</p><p>&sect; <em>Special senses: </em>taste perversion.</p><p>&sect; <em>Urinary: </em>haematuria, micturition disorder, dysuria, strangury, anuria.</p><p>&nbsp;</p><p>*&nbsp;&nbsp; Very rare cases of long lasting (up to months or years) or permanent adverse drug reactions, such as tendon inflammations, tendon rupture, joint pain, pain in the limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, burning, numbness or pain (neuropathy), depression, fatigue, sleep disorders, memory impairment, as well as impairment of hearing, vision, and taste and smell have been associated with administration of quinolone and fluoroquinolone antibiotics, in some cases irrespective of pre-existing risk factors.</p><p>**&nbsp; Cases of an enlargement and weakening of the aortic wall or a tear in the aortic wall (aneurysms and dissections), which may rupture and may be fatal, and of leaking heart valves have been reported in patients receiving fluoroquinolones. See also section 2.</p><p><strong>Adverse laboratory events</strong></p><p>Changes in laboratory parameters, listed as adverse events, without regard to drug relationship include:</p><p>&sect; <em>Hematologic: </em>monocytosis (0.2%), eosinophilia (0.1%), leukopenia (0.1%), leukocytosis (0.1%).</p><p>&sect; <em>Renal: </em>elevated BUN (0.1%), decreased potassium (0.1%), increased creatinine (0.1%).</p><p>&sect; <em>Hepatic: </em>elevations of ALT (SGPT) (0.4%), AST (SGOT) (0.3%), bilirubin (0.1%), alkaline phosphatase (0.1%).</p><p>Additional laboratory changes occurring in &lt; 0.1% in the clinical studies included: elevation of serum gamma glutamyl transferase, decrease in total protein or albumin, prolongation of prothrombin time, anaemia, decrease in haemoglobin, thrombocythemia, thrombocytopenia, abnormalities of urine specific gravity or serum electrolytes, increased albumin, elevated ESR, albuminuria, macrocytosis.</p><p><u>Post-Marketing Adverse Events</u></p><p>Adverse events reported from worldwide marketing experience with lomefloxacin are: anaphylaxis, cardiopulmonary arrest, laryngeal or pulmonary oedema, ataxia, cerebral thrombosis, hallucinations, painful oral mucosa, pseudomembranous colitis, haemolytic anaemia, hepatitis, tendinitis, diplopia, photophobia, phobia, exfoliative dermatitis, hyperpigmentation, Stevens-Johnson syndrome, toxic epidermal necrolysis, dysgeusia, interstitial nephritis, polyuria, renal failure, urinary retention, and vasculitis.</p><p><em><u>Quinolone-class adverse events</u></em></p><p>Additional quinolone-class adverse events include: peripheral neuropathy, torsades de pointes, erythema nodosum, hepatic necrosis, possible exacerbation of myasthenia gravis, dysphasia, nystagmus, intestinal perforation, manic reaction, renal calculi, acidosis and hiccough.</p><p>Laboratory adverse events include: agranulocytosis, elevation of serum triglycerides, elevation of serum cholesterol, elevation of blood glucose, elevation of serum potassium, albuminuria, candiduria, and crystalluria.</p><p><strong>&nbsp;</strong></p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>You can also report side effects directly via:</p><p>&sect; <strong>Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2340</p><p><strong>SFDA Call centre:</strong> 19999</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p><p>&sect; <strong>Other GCC States: </strong>Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Do not take <strong>Lomax</strong> after the expiry date which is stated on the carton and blister.</p><p>-&nbsp; Store below 30&deg;C, in a dry place, protected from light.</p><p>-&nbsp; Do not take <strong>Lomax</strong> if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each film-coated tablet contains:</p><p><em>Active ingredient: </em>Lomefloxacin HCl equivalent to lomefloxacin 400mg.</p><p><em>Other ingredients</em>: Lactose monohydrate, carboxymethyl cellulose calcium, hydroxyl propyl cellulose, polyoxyl 40 stearate, magnesium stearate, hypromellose, polyethylene glycol 6000, titanium dioxide and talc.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lomax Tablets are supplied in packs containing 5 or 10 tablets in one blister.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot;Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                19/11/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong><u>العلاج</u></strong></p><p dir="RTL">تستخدم أقراص <strong>لوماكس </strong>المكسوة (لوميفلوكساسين هيدروكلوريد) لعلاج البالغون في الحالات التالية:</p><p dir="RTL"><strong>&sect;&nbsp; </strong><strong>الجهاز التنفسي ال</strong><strong>سفلي: </strong></p><p dir="RTL">-&nbsp; التفاقم البكتيري الحاد لالتهاب الشعب الهوائية المزمن.</p><p dir="RTL"><strong>&sect;&nbsp; </strong><strong>الجهاز البولي: </strong></p><p dir="RTL">-&nbsp; العدوى البسيطة في المسالك البولية &nbsp;(التهاب المثانة). &nbsp;</p><p dir="RTL">-&nbsp; العدوى المضاعفة في المسالك البولية.</p><p dir="RTL"><strong><u>الوقاية </u></strong></p><p dir="RTL">يستخدم <strong>لوماكس </strong>قبل إجراء العمليات الجراحية للحد من حدوث العدوى في الحالات التالية:</p><p dir="RTL">&sect;&nbsp; أخذ خزعة البروستاتا من خلال المستقيم: للحد من حدوث عدوى المسالك البولية في مرحلة مبكرة أو متأخرة من بعد إجراء العملية الجراحية (بعد مرور 3 - 5 أيام أو &nbsp;3 - 4 أسابيع من إجراء العملية الجراحية).</p><p dir="RTL">&sect;&nbsp; العمليات الجراحية في المسالك البولية من خلال الإحليل: للحد من حدوث عدوى المسالك البولية في مرحلة مبكرة من بعد إجراء العملية الجراحية (بعد مرور 3 - 5 أيام من إجراء العملية الجراحية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم تناول لوماكس:</strong></p><p dir="RTL"><strong>&sect;&nbsp; </strong>إذا كنت تعاني من الحساسية تجاه المادة الفعالة لوميفلوكساسين أو تجاه أياً من المواد الغير فعالة الأخرى في هذا الدواء (المذكورة في البند رقم 6) أو إذا عانيت مسبقاً من فرط الحساسية تجاه المضادات الحيوية الأخرى من مجموعة<strong> </strong>الكوينولون.</p><p dir="RTL"><strong>يجب عدم استعمال المضادات الحيوية من مجموعة الفلوروكينولون (على سبيل المثال لوميفلوكساسين) في الحالات التالية:</strong></p><p dir="RTL">&sect;&nbsp; لعلاج حالات العدوى التي قد تتحسن دون علاج أو ليست شديدة (مثل عدوى الحنجرة)؛</p><p dir="RTL">&sect;&nbsp; لعلاج حالات العدوى الغير بكتيرية، على سبيل المثال. التهاب البروستاتا غير الجرثومي (المزمن)؛</p><p dir="RTL">&sect;&nbsp; للوقاية من حدوث إسهال السفر أو للحد من التهابات المسالك البولية (عدوى المجرى البولي الغير ممتدة خارج المثانة)؛</p><p dir="RTL">&sect;&nbsp; لعلاج حالات العدوى البكتيرية الطفيفة أو المتوسطة ما لم يكن من الممكن استخدام أدوية أخرى مضادة للبكتيريا موصى بها لعلاج مثل هذه الحالات من العدوى.</p><p dir="RTL">يجب <strong>تجنب</strong> المضادات الحيوية من مجموعة الفلوروكينولون بشكل عام في المرضى الذين عانوا مسبقاً من تأثيرات جانبية خطيرة مع المضادات الحيوية من مجموعة الفلوروكينولون أو الكوينولون .</p><p dir="RTL"><strong>يجب توخي الحذر</strong> لاسيما عند استخدام المضادات الحيوية من مجموعة الفلوروكينولون لدى كبار السن، والمرضى الذين يعانون من أمراض الكلى وأولئك الذين أجريت لهم عملية زرع عضو حيث أن هؤلاء المرضى يكونون أكثر عرضة لإصابة الأوتار.</p><p dir="RTL">وبما أن استخدام الكورتيكوستيرويدات بالتزامن مع المضادات الحيوية من مجموعة الفلوروكينولون يزيد أيضًا من هذه المخاطر، فيجب تجنب الاستخدام المشترك لهذه الأدوية.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong><u>قد تسبب المضادات الحيوية من مجموعة </u></strong><strong><u>الفلوروكينولون </u></strong><strong><u>في حدوث ما يلي: </u></strong></p><p dir="RTL"><strong>&sect; </strong><strong>انخفاض في مستويات سكر الدم بصورة كبيرة: </strong>قد يؤدي انخفاض مستويات سكر الدم إلى حدوث مشاكل خطيرة بما في ذلك الغيبوبة، وذلك بصفة خاصة لدى المرضى من فئة كبار السن و المرضى الذين يعانون من داء السكري ويتلقون الأدوية التي تعمل على خفض مستويات سكر الدم.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تتلقى العلاج باستخدام مضادات السكري عندما يصف لك العلاج باستخدام مضادٍ حيوي، وكما يجب عليك إخباره إذا عانيت من انخفاض في مستويات سكر الدم أو أعراض لحدوث ذلك أثناء فترة تلقي مضادٍ حيوي من مجموعة الفلوروكينولون. في حال المرضى الذين يعانون من داء السكري، فقد يرغب طبيبك المعالج بإجراء فحوصات للتأكد من مستويات سكر الدم في كثير من الأحيان أثناء فترة تلقي العلاج باستخدام مضادٍ حيوي من مجموعة الفلوروكينولون.</p><p dir="RTL">&nbsp;تتضمن علامات الأعراض الأولية لحدوث انخفاض في مستويات سكر الدم على: ارتباك، نبضات قلب قوية، تسارع نبضات القلب، دوخة، شحوب لون الجلد، الشعور بالارتعاش، تعرق، الشعور بالجوع بصورة غير اعتيادية، صداع، الشعور بالضعف، توهج والشعور بالقلق بصورة غير اعتيادية.</p><p dir="RTL">&nbsp;يرجى منك مناقشة طبيبك المعالج حول الإجراءات اللازمة التي يجب اتخاذها عند حدوث انخفاض في مستويات سكر الدم. من الممكن أن تتفاقم أعراض انخفاض مستويات سكر الدم وتصبح مهددة للحياة، لذلك يرجى منك طلب المساعدة الطبية أو التوجه إلى قسم الطوارئ في أقرب مستشفى في حال حدوث أعراض أكثر خطورة بما في ذلك ارتباك، عدم القدرة على استكمال المهام اليومية، عدم وضوح في الرؤية، نوبات تشنجية أو فقدان الوعي.</p><p dir="RTL">&sect; <strong>تأثيرات معينة على الصحة العقلية: ا</strong>ضطراب في الوعي الإدراكي، توهان، هياج، عصبية، اضطراب في الذاكرة، وحدوث اضطرابات خطيرة في القدرة العقلية تعرف باسم الهذيان . يرجى منك إخبار طبيبك المعالج على الفور في حال ملاحظة حدوث تغيرات في المزاج، السلوك الشخصي أو التفكير.</p></td></tr></tbody></table><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج قبل تناول لوماكس في الحالات التالية: </strong></p><p dir="RTL"><strong>&sect;&nbsp; </strong>إذا كنتِ حاملاً أو ترضعين طفلك رضاعة طبيعية</p><p dir="RTL"><strong>&sect;&nbsp; </strong>إذا كنت بعمر أقل من 18 سنة.</p><p dir="RTL">&sect;&nbsp; إذا كنت تعاني من الصرع أو حالة مرضية والتي من المحتمل أن تجعلك تصاب باختلاجات، يرجى منك التحدث مع طبيبك المعالج قبل تناول <strong>لوماكس</strong>.</p><p dir="RTL">&sect;&nbsp; إذا كنت تعاني أو عانيت مسبقاً من أي مشاكل صحية عقلية، يرجى منك استشارة طبيبك المعالج قبل تناول <strong>لوماكس</strong>.</p><p dir="RTL">&sect;&nbsp; قد تسبب الأدوية من مجموعة الكوينولون في تحفيز الجهاز العصبي المركزي، والذي قد يؤدي إلى حدوث ارتعاش، أرق، دوار، ارتباك، هلوسة. في حال حدوث أي من هذه التفاعلات لدى المرضى الذين يتلقون العلاج باستخدام <strong>لوماكس</strong>، فيجب التوقف عن تناوله واتخاذ الإجراءات الملائمة.</p><p dir="RTL">&sect;&nbsp; من الممكن أن يؤدي <strong>لوماكس</strong> إلى حدوث تغيرات في تخطيط كهربائية القلب (إطالة فترة الكيو تي/ تورساد دي بوانت)، وبصفة&nbsp; خاصة&nbsp; إذا كنت أنثى، إذا كنت من فئة كبار السن (بعمر أكبر من 60 سنة)، إذا كنت تعاني من اضطرابات في القلب أو كنت تتلقى عدة أدوية.</p><p dir="RTL">&sect;&nbsp; قد تعاني من أعراض تلف الأعصاب (الاعتلال العصبي المحيطي) على سبيل المثال ألم، حرقان، تنميل، تخدر و/أو الشعور بالضعف وبصفة خاصة تصيب القدمين والساقين أو اليدين والذراعين. في حال حدوث ذلك، يرجى منك إخبار طبيبك المعالج على الفور قبل الاستمرار في تلقي العلاج باستخدام <strong>لوماكس</strong>.</p><p dir="RTL"><strong>&sect;&nbsp; </strong>قد يتسبب <strong>لوماكس</strong> في حدوث ألم والتهاب في الأوتار. يزداد خطر حدوث التهاب وتمزق في الأوتار إذا كنت من فئة كبار السن أو إذا كنت تتناول أيضاً كورتيكوستيرويدات. مع حدوث أول علامة من الألم أو الالتهاب، يجب عليك التوقف عن تناول <strong>لوماكس</strong>، قم بوضع الأطراف المصابة في وضع مريح وقم باستشارة طبيبك المعالج على الفور. تجنب أي تمرين غير ضروري حيث من الممكن أن يزيد من خطر حدوث تمزق الوتر. من الممكن أن يحدث تمزق في الأوتار أثناء أو بعد تلقي العلاج باستخدام الأدوية من مجموعة الكوينولون، بما في ذلك لوميفلوكساسين.</p><p dir="RTL">&sect;&nbsp; قد تعاني من الإسهال أثناء أو بعد تناول المضادات الحيوية بما في ذلك <strong>لوماكس </strong>(سجل حدوث التهاب القولون الغشائي الكاذب عند استعمال ما يقارب جميع المضادات الحيوية بما في ذلك لوميفلوكساسين، وقد تتراوح شدته من طفيف إلى مهدد للحياة). في حال زيادة حدة الحالة المرضية أو استمرت لفترة طويلة أو لاحظت ظهور دم أو مخاط في البراز، يجب عليك التوقف عن تناول <strong>لوماكس </strong>على الفور واستشارة طبيبك المعالج. يجب عدم تناول الأدوية التي تعمل على توقف أو تباطؤ حركة الأمعاء.</p><p dir="RTL">&sect;&nbsp; قد تعاني من تفاعلات فرط الحساسية الخطيرة أو من المحتمل أن تكون مهددة للحياة، ومفاجئ (تفاعلات تأقية /صدمة الحساسية) ومن الممكن أن تحدث أثناء تناول الجرعة الأولى من هذا الدواء. بعض التفاعلات تكون مصحوبة بحدوث هبوط الدورة الدموية، فقدان الوعي، وخز، وذمة البلعوم أو الوجه، ضيق التنفس، شرى أو حكة. في حال حدوث ذلك، يرجى منك التوقف عن تناول <strong>لوماكس </strong>واطلب المشورة الطبية على الفور.</p><p dir="RTL">&sect;&nbsp; إذا تم تشخيص إصابتك&nbsp; بتضخم أو &quot;انتفاخ&quot; في الأوعية الدموية الكبيرة (تمدد الأوعية الدموية الأبهري أو تمدد الأوعية الدموية المحيطية الكبيرة).</p><p dir="RTL">&sect;&nbsp; إذا عانيت مسبقاً من حدوث تمزق الأبهر&nbsp; (تمزق في جدار الأبهر).</p><p dir="RTL">&sect;&nbsp; إذا تم تشخيصك بتسريب صمامات القلب (ارتجاع صمام القلب).</p><p dir="RTL">&sect;&nbsp; إذا كان لديك تاريخ عائلي مرضي بالإصابة بتمدد الأوعية الدموية الأبهري أو تمزق أبهري أو أمراض صمام القلب الخلقية أو أية عوامل خطر أو حالات مرضية تتسبب في حدوث ذلك (على سبيل المثال اضطرابات النسيج الضام مثل متلازمة مارفان أو متلازمة إهلرز دانلوس الوعائية، متلازمة تيرنر، متلازمة شوغرن [أحد أمراض التهاب المناعة الذاتية] أو اضطرابات الأوعية الدموية على سبيل المثال التهاب الشرايين تاكاياسو، التهاب الشريان ذو الخلايا العملاقة، داء بهجت، ارتفاع ضغط الدم أو تصلب الشرايين، والتهاب المفاصل الروماتويدي [مرض المفاصل] أو التهاب الشغاف [عدوى القلب]).</p><p dir="RTL">&sect;&nbsp; إذا كنت تعاني من اضطرابات في وظائف الكلى (الكرياتينين &lt; 40 ملليلتر/دقيقة/1.73م<sup>2</sup>).</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم إعطاء هذا الدواء للأطفال والمراهقين بعمر أقل من 18 سنة، ذلك لأنه لم تثبت مدى كفاءة وسلامة هذا الدواء بالنسبة لهذه الفئة العمرية.</p><p dir="RTL">أثناء تناول <strong>لوماكس</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج على الفور إذا حدث لك اي مما يلي أثناء تناول <strong>لوماكس</strong>، سوف يقرر طبيبك المعالج اذا ما كنت بحاجة للتوقف عن تناول هذا الدواء.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>آثار جانبية خطيرة طويلة الأمد ومسببة للعجز ولا رجعة فيها</strong><strong>&nbsp; </strong>ارتبطت المضادات الحيوية من مجموعة الفلوروكينولون / الكينولون ، بما في ذلك <strong>لوميفلوكساسين </strong>، بآثار جانبية نادرة جدًا ولكنها خطيرة ، وبعضها طويل الأمد (يستمر لأشهر أو سنوات) ، أو يسبب الإعاقة أو لا رجعة فيه. ويشمل ذلك آلام الأوتار، العضلات والمفاصل في الأطراف العلوية والسفلية، صعوبة في المشي، الشعور الغير طبيعي مثل الشعور بوخز الإبر، الدغدغة، التنميل أو الحرق (تنمل) ، والاضطرابات الحسية بما في ذلك ضعف البصر، التذوق، الشم، والسمع، الاكتئاب، ضعف الذاكرة، التعب الشديد و اضطرابات النوم الشديدة. إذا واجهت أيًا من هذه الآثار الجانبية بعد تناول لوميفلوكساسين ، قم بالاتصال بطبيبك المعالج على الفور قبل الاستمرار في تلقي العلاج. ستقرر أنت وطبيبك المعالج الاستمرار في تلقي العلاج مع الأخذ في الاعتبار أيضًا مضاد حيوي من مجموعة أخرى</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى منك التوجه إلى غرفة الطوارئ على الفور إذا كنت <strong>تشعر بألم شديد ومفاجئ في بطنك، صدرك أو ظهرك</strong>، والذي يمكن أن يكون من أعراض تمدد أو تمزق الأوعية الدموية الأبهري قد تزداد خطورة هذه الأعراض إذا كنت تتعالج بالكورتيكوستيرويدات الجهازية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى منك إخبار طبيبك المعالج ع الفور إذا بدأت تعاني من <strong>بداية مفاجئة لضيق التنفس</strong>، خاصةً عند الاستلقاء على سريرك ، أو لاحظت ت<strong>ورمًا في الكاحلين، القدمين أو البطن</strong> ، أو <strong>بداية لخفقان القلب</strong> (الإحساس بنبض قلب سريع أو غير منتظم)</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن مع لوماكس</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه حول أية أدوية أخرى تتناولها، تناولتها مؤخراً أو قد تتناولها.</p><p dir="RTL"><u>قبل تناول <strong>لوماكس</strong>، يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول أياً من الأدوية التالية: </u></p><p dir="RTL">&sect;&nbsp; من الممكن أن تقلل أية أدوية تحتوي على المغنيسيوم أو الألومينيوم (على سبيل المثال مضادات الحموضة التي تستخدم لعلاج عسر الهضم)، أو ديدانوسين أو أية أدوية أخرى تحتوي على سكرالفات (تستخدم لعلاج اضطرابات المعدة) من امتصاص لوميفلوكساسين. لذلك، يجب تناول أيٍ من المستحضرات السابق ذكرها قبل تناول لوميفلوكساسين بأربعة ساعات أو بعده بساعتين.</p><p dir="RTL">&sect;&nbsp; بروبنسيد، قد يقلل من طرح لوميفلوكساسين عند تزامن تناولهما معاً.</p><p dir="RTL">&sect;&nbsp; مضادات التخثر الفموية (على سبيل المثال وارفارين أو إحدى مشتقاته)، قد يزداد المفعول المضاد لتخثر الدم لهذه الأدوية عند تزامن تناولها مع لوميفلوكساسين، فقد يكون من الضروري أن يقوم طبيبك المعالج بمراقبة زمن تجلط الدم لديك.</p><p dir="RTL"><u>يجب توخي الحذر أثناء فترة تناول أياً من الأدوية التالية:</u></p><p dir="RTL">&sect;&nbsp; سيكلوسبورين، حيث أن الأدوية الأخرى من مجموعة الكوينولون قد تزيد من تركيز سيكلوسبورين في المصل، لذلك يجب مراقبة تركيز عند تزامن تناوله مع لوميفلوكساسين.</p><p dir="RTL"><strong>&sect;&nbsp; </strong>الكافيين، يفضل تجنب الاستعمال المتزامن للوميفلوكساسين مع الكافيين، حيث أن الأدوية الأخرى من مجموعة الكوينولون قد تؤثر على عملية أيض الكافيين مما يؤدي إلى تقليل مقدار تصفيته، وبذلك فهو يزيد من عمر النصف له ومن خطر حدوث تحفيز للجهاز العصبي المركزي.&nbsp;</p><p dir="RTL"><strong>&sect;&nbsp; </strong>سيميتيدين، لقد ظهر أنه قد يؤثر على طرح الأدوية الأخرى من مجموعة الكوينولون.</p><p dir="RTL"><u>يرجى منك إخبار طبيبك المعالج إذا كنت تتناول أياً من الأدوية التالية:</u></p><p dir="RTL">&sect;&nbsp; فينيتوين</p><p dir="RTL">&sect;&nbsp; ثيوفيلين</p><p dir="RTL">&sect;&nbsp; أوميبرازول</p><p dir="RTL">&sect;&nbsp; تيرفينادين</p><p dir="RTL"><strong>التعرض لأشعة الشمس</strong></p><p dir="RTL">قد تؤدي المضادات الحيوية من مجموعة الكوينولون &nbsp;إلى الحساسية المفرطة للجلد تجاة أشعة الشمس أو عند التعرض للأشعة فوق البنفسجية. يجب عليك تجنب التعرض الطويل لأشعة الشمس أو أشعة الشمس القوية ويجب عدم استخدام الحمامات الشمسية أو أية مصابيح أخرى للأشعة فوق البنفسجية أثناء تناول <strong>لوماكس</strong>. قد يتم تقليل خطر حدوث السمية الضوئية عن طريق تناول الجرعة اليومية من <strong>لوماكس </strong>قبل التعرض للشمس لمدة لا تقل عن 12 ساعة (على سبيل المثال أثناء فترة المساء). يرجى منك التوقف عن تلقي العلاج باستخدام <strong>لوماكس </strong>عند ظهور أول أعراض أو علامات حدوث السمية الضوئية الأولية على سبيل المثال الشعور بالحرقة في الجلد، إحمرار، تورم، تقرحات، طفح جلدي، حكة أو التهاب الجلد.</p><p dir="RTL"><strong>لوماكس</strong><strong> </strong><strong>مع الطعام والشراب</strong></p><p dir="RTL">من الممكن تناول <strong>لوماكس</strong> مع أو بدون الطعام.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية و الخصوبة</strong></p><p dir="RTL">يجب عدم تناول <strong>لوماكس</strong> إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL">إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل، يرجى منك استشارة الطبيب المعالج أو الصيدلي الذي تتعاملين معه لطلب النصيحة قبل تناول هذا الدواء.</p><p dir="RTL">لا تشير الدراسات التي أجريت على الحيوانات أنه سوف تقل الخصوبة عند تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يؤدي تناول <strong>لوماكس</strong> إلى الشعور بالدوخة أو الدوار، قد يؤدي إلى فقدان مفاجئ ومؤقت للبصر، أو حدوث إغماء لفترة قصيرة. إذا حدث ذلك لك يجب عليك عدم القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات لوماكس</strong></p><p dir="RTL">يحتوي<strong> لوماكس</strong> على اللاكتوز. &nbsp;يرجى منك التحدث إلى طبيبك المعالج قبل تناول <strong>لوماكس</strong>، إذا كان قد أخبرك طبيبك المعالج مسبقاً بأنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك تناول هذا الدواء دائماً بدقة وفقاً للتعليمات المذكورة في هذه النشرة أو وفقاً لتعليمات طبيبك المعالج أو الصيدلي الذي تتعامل معه. يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه إن لم تكن متأكداً من ذلك.</p><p dir="RTL"><strong><u>العلاج</u></strong></p><p dir="RTL">للمرضى الذين لديهم وظائف الكلى طبيعية.</p><p dir="RTL">يبلغ مقدار الجرعة اليومية الموصى بها من <strong>لوماكس </strong>على النحو التالي:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>العدوى</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مقدار الجرعة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>التكرار</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مدة العلاج</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مقدار الجرعة اليومية</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التفاقم البكتيري الحاد لالتهاب الشعب الهوائية المزمن</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">مرة واحدة يومياً</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">10 أيام</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">العدوى البسيطة في المسالك البولية &nbsp;(التهاب المثانة) &nbsp;التي تسببها إشيريشيا كولاي لدى النساء</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">مرة واحدة يومياً</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">3 أيام</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">العدوى البسيطة في المسالك البولية &nbsp;(التهاب المثانة( &nbsp;التي تسببها كليبسيلا نيمونيا، أو بروتياس ميرابلس، أو ستافيلوكوكس سابروفايتكس</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">مرة واحدة يومياً</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">10 أيام</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">العدوى المضاعفة في المسالك البولية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">مرة واحدة يومياً</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">14 يوماً</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">400 ملغم</p></td></tr></tbody></table><p dir="RTL"><strong>المرضى من فئة كبار السن </strong></p><p dir="RTL">لا يتطلب تعديل مقدار الجرعة للمرضى من فئة كبار السن الذين لديهم وظائف كلى طبيعية (الكرياتينين &ge; 40 ملليلتر/دقيقة/1.73م<sup>2</sup>).</p><p dir="RTL"><strong>إذا تناولت لوماكس بجرعة أكبر مما يجب</strong></p><p dir="RTL">إذا تناولت أكثر من الجرعة الموصى بها، يرجى منك طلب المساعدة الطبية على الفور. حاول أن تأخذ معك أية أقراص متبقية، عبوة الدواء أو هذه النشرة معك حتى يتمكن الطبيب المعالج أو الصيدلي الذي تتعامل معه معرفة الدواء الذي قمت بتناوله.</p><p dir="RTL"><strong>إذا سهوت عن تناول لوماكس</strong></p><p dir="RTL">إذا سهوت عن تناول إحدى الأقراص، يجب عليك تناولها في أقرب وقت ممكن حال تذكرها في نفس اليوم. إذا لم تتذكر الجرعة التي قد سهوت عنها في نفس اليوم، تناول جرعتك المعتادة في اليوم التالي. يجب عدم تناول جرعة مضاعفة لتعويض الجرعة التي قد سهوت عنها.</p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، مالم تكن متأكداً ما الذي يجب عليك فعله في حال السهو عن تناول هذا الدواء.</p><p dir="RTL"><strong>إذا توقفت عن تناول لوماكس</strong></p><p dir="RTL">إذا توقفت عن تناول هذا الدواء بعد فترة قصيرة جداً من بدء العلاج، قد لا تتماثل حالة العدوى لديك للشفاء تماماً. يرجى منك استشارة طبيبك المعالج إذا كنت ترغب بالتوقف عن تناول الأقراص قبل إنهاء دورة العلاج المحددة لك.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي <strong>لوماكس</strong> إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص.</p><p dir="RTL">في التجارب السريرية، معظم التأثيرات الجانبية التي تم تسجيلها كانت معدل شدتها من طفيفة إلى متوسطة وكانت تأثيرات عابرة. أثناء فترة التحقيقات الإكلينيكية، تلقى 5623 مريضاً العلاج باستخدام &nbsp;لوميفلوكساسين. توقف المرضى عن تلقي العلاج باستخدام&nbsp; لوميفلوكساسين بمعدل 2.2٪، وذلك لحدوث تأثيرات جانبية، تضمن ذلك بصورة أساسية على تأثيرات الجهاز الهضمي (0.7٪)، الجلد (0.7٪) أو الجهاز العصبي المركزي (0.5٪).</p><p dir="RTL"><strong>التأثيرات الجانبية الإكلينيكية </strong></p><p dir="RTL">التأثيرات الجانبية الأكثر شيوعاً التي سجل حدوثها بمعدل (&ge; 1٪) من المرضى، بغض النظر عن صلتها بالدواء هي: صداع (3.6٪)، غثيان (3.5٪)، حساسية تجاه ضوء (2.3٪)، دوخة (2.1٪)، إسهال (1.4٪)، وألم في البطن (1.2 ٪).</p><p dir="RTL">تم ذكر التأثيرات الجانبية الإكلينيكية أدناه التي سجل حدوثها بمعدل &lt; 1٪ من المرضى الذين تلقوا العلاج باستخدام لوميفلوكساسين، بغض النظر عن صلتها بالدواء على النحو التالي:</p><p dir="RTL">&sect;&nbsp; التأثيرات اللاإرادية: فرط التعرق، جفاف الفم، احمرار، فقدان الوعي.</p><p dir="RTL">&sect;&nbsp; &nbsp;الجسم بأكمله: الشعور بالتعب، ألم في الظهر، توعك، الوهن، ألم في الصدر ، وذمة الوجه ، هبات ساخنة ، وأعراض مماثلة لأعراض الإنفلونزا، وذمة، قشعريرة ، تفاعلات تحسسية، تفاعلات تأقية، انخفاض قدرة تحمل الحرارة.</p><p dir="RTL">&sect;&nbsp; القلب والأوعية الدموية: تسارع ضربات القلب، ارتفاع ضغط الدم، انخفاض ضغط الدم، احتشاء عضلة القلب، الذبحة الصدرية ، قصور القلب، تباطؤ ضربات القلب، عدم انتظام ضربات القلب، التهاب الوريد، انسداد الشريان الرئوي، انقباضات خارجة، اضطرابات الدماغية الوعائية، زرقة ، اعتلال عضلة القلب.</p><p dir="RTL">&sect;&nbsp; الجهاز العصبي المركزي والمحيطي: ارتعاش، دوار، تنميل، وخز، فرط التوتر، اختلاجات، فرط الحركة، غيبوبة.</p><p dir="RTL">&sect;&nbsp; الجهاز الهضمي: عسر الهضم، تقيؤ، انتفاخ، إمساك ، نزيف من الجهاز الهضمي، عسر البلع، التهاب الفم ، تغير لون اللسان، والتهاب الجهاز الهضمي.</p><p dir="RTL">&sect;&nbsp; السمع: ألم في الأذن، طنين الأذن.</p><p dir="RTL">&sect;&nbsp; اضطرابات الدم: فرفرية، تضخم العقد اللمفية ، كثرة الصفيحات، فقر الدم ، قلة الصفيحات، زيادة انحلال الفايبرين.</p><p dir="RTL">&sect;&nbsp; الكبد: اضطراب في وظائف الكبد.</p><p dir="RTL">&sect;&nbsp; الأيض: العطش، ارتفاع سكر الدم ، نقص سكر الدم، داء نقرس.</p><p dir="RTL">&sect;&nbsp; الجهاز العضلي الهيكلي: ألم في المفاصل، ألم في العضل، تشنجات في الساق.</p><p dir="RTL">&sect;&nbsp; طب العيون: اضطراب في الرؤية، التهاب الملتحمة، رهاب الضوء، ألم في العين ، سيلان الدموع بصورة غير طبيعية.</p><p dir="RTL">&sect;&nbsp; الاضطرابات النفسية: أرق، عصبية، الشعور بالنعاس، فقدان الشهية، اكتئاب، ارتباك، هياج، زيادة الشهية، اضطراب تبدد الشخصية، جنون الارتياب، قلق، حلم مرضي، اضطراب في التفكير، ضعف التركيز.</p><p dir="RTL">&sect;&nbsp; الجهاز التناسلي: لدى النساء: داء&nbsp;المبيضات&nbsp;المهبلي، التهاب المهبل، الثر الأبيض، اضطراب الحيض، ألم العجان، نزيف بين الحيض. لدى الرجال: التهاب البربخ، التهاب الخصية.</p><p dir="RTL">&sect;&nbsp; آلية المقاومة: العدوى الفيروسية، داء&nbsp;المبيضات&nbsp;، العدوى الفطرية.</p><p dir="RTL">&sect;&nbsp; الجهاز التنفسي: عدوى الجهاز التنفسي، التهاب الأنف، التهاب البلعوم ، ضيق التنفس، سعال، رعاف، تشنج قصبي، اضطراب في الجهاز التنفسي، زيادة البلغم، صرير، نقص التهوية.</p><p dir="RTL">&sect;&nbsp; الجلد / الحساسية: حكة، طفح جلدي، شرى ، تقشر الجلد ، الطفح الفقاعي، إكزيما، اضطرابات الجلد، حب الشباب ، تغير لون الجلد، تقرحات جلدية، وذمة وعائية. (انظر أيضًا الجسم بأكمله.)</p><p dir="RTL">&sect;&nbsp; الحواس الخاصة: اضطراب في حاسة التذوق.</p><p dir="RTL">&sect;&nbsp; المسالك البولية: البول الدموي، اضطرابات في التبول، عسر التبول ، تقطر البول، احتباس البول.</p><p dir="RTL">* &nbsp;&nbsp;حالات نادرة جدًا من تفاعلات دوائية طويلة الأمد (تستمر إلى أشهر أو سنوات) أو دائمة، مثل التهاب الأوتار، تمزق الأوتار، آلام المفاصل، آلام في الأطراف، صعوبة في المشي، وأحاسيس غير طبيعية مثل وخز الدبابيس والإبر، الدغدغة، الحرق، التنميل أو الألم (الاعتلال العصبي)، الاكتئاب، التعب، اضطرابات النوم، ضعف الذاكرة، بالإضافة إلى ضعف السمع، الرؤية، الذوق والشم وقد ظهرت هذه الأعراض عند إعطاء المضادات الحيوية من مجموعة الكينولون والفلوروكينولون ، في بعض الحالات بغض النظر عن عوامل الخطر الموجودة مسبقاً.</p><p dir="RTL">**&nbsp;&nbsp; تم الإبلاغ عن حالات تضخم وضعف في جدار الأبهر أو تمزق جدار الأبهر (تمدد و تمزق الأوعية الدموية)، والتي من الممكن ان تتمزق أو ان تكون قاتلة، كما تم الإبلاغ عن حالات تسرب في&nbsp;&nbsp; صمامات القلب لدى المرضى الذين يتلقون الفلوروكينولونات. انظر أيضًا القسم 2.</p><p dir="RTL"><strong>التأثيرات الجانبية المختبرية</strong></p><p dir="RTL">سجلت التغييرات في المعلمات المختبرية على هيئة تأثيرات جانبية بغض النظر عن علاقتها بالدواء على النحو التالي:</p><p dir="RTL">&sect;&nbsp; اضطرابات الدم: كثرة الوحيدات (0.2 ٪) ، فرط الحمضات (0.1 ٪)، نقص الكريات البيضاء (0.1 ٪) ، كثرة الكريات البيضاء (0.1 ٪).</p><p dir="RTL">&sect;&nbsp; الكلى: ارتفاع مستوى نيتروجين يوريا الدم (0.1 ٪)، وانخفاض مستوى البوتاسيوم (0.1 ٪)، ارتفاع مستوى الكرياتينين (0.1 ٪).</p><p dir="RTL">&sect;&nbsp; الكبد: ارتفاع مستوى&nbsp; كلاً من ناقلة أمين الألانين (مصل&nbsp;الغلوتاميك للالبيروفيك)&nbsp;(0.4 ٪)، ناقلة أمين الأسبارتات ( ترانس أميناز الجلوتاميك) (0.3٪)، بيليروبين (0.1 ٪) وفوسفاتاز قلوي (0.1 ٪).</p><p dir="RTL">تتضمن التغيرات المختبرية الإضافية التي سجل حدوثها بمعدل &lt; 0,1٪ في الدراسات الإكلينيكية على:&nbsp; ارتفاع مستوى ناقلة الببتيد غاما غلوتاميل في مصل الدم، انخفاض البروتين الكلي أو ألبيومين، إطالة زمن البروثرومبين، فقر الدم، وانخفاض مستوى الهيموجلوبين، كثرة الصفيحات، قلة الصفيحات،&nbsp;قيمة الكثافة النوعية للبول الغير طبيعي أو مستوى الإلكتروليتات&nbsp;في المصل، ارتفاع مستوى ألبيومين، ارتفاع سرعة ترسب الدم، بيلة الألبومين، كريات دم حمراء كبيرة.</p><p dir="RTL"><u>التأثيرات الجانبية أثناء فترة ما بعد التسويق</u></p><p dir="RTL">التأثيرات الجانبية التي سجل حدوثها أثناء تجربة تسويق لوميفلوكساسين في جميع أنحاء العالم: &nbsp;صدمة الحساسية، الاعتلال القلبي الرئوي، وذمة الحنجرة أو وذمة رئوية، ترنح، تخثر دماغي، هلوسة، ألم في الغشاء المخاطي للفم، التهاب القولون الغشائي الكاذب، فقر الدم الانحلالي، التهاب الكبد، التهاب الأوتار، ازدواج الرؤية، رهاب الضوء، الرهاب، التهاب الجلد التقشري، فرط التصبغ، متلازمة ستيفن جونسون، انحلال البشرة السمي التنخري، اضطراب في حاسة التذوق، التهاب الكلية الخلالي، تعدد البيلات، قصور كلوي، احتباس البول والتهاب الأوعية الدموية.&nbsp;</p><p dir="RTL"><u>التأثيرات الجانبية الناجمة عن الأدوية من مجموعة الكوينولون </u></p><p dir="RTL">تتضمن التأثيرات الجانبية الإضافية الناجمة عن الأدوية من مجموعة الكوينولون: اعتلال الأعصاب المحيطية، تورساد دي بوانت، الحمامي العقدية، نخر كبدي، احتمالية حدوث تفاقم للون العضلي الوبيل، صعوبة النطق، الرّأرأ&nbsp;، انثقاب الأمعاء، نوبة هوس، الحصاه الكلوية، الحماض، فواق.</p><p dir="RTL">تتضمن التأثيرات الجانبية المختبرية على: ندرة المحببات، ارتفاع مستوى ثلاثي الغليسريد في الدم، ارتفاع مستوى الكوليسترول في الدم، ارتفاع مستوى السكر في الدم، ارتفاع البوتاسيوم في المصل، بيلة الألبومين، بيلة المبيضات وزيادة بلورات البول.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL">&sect;&nbsp;&nbsp; <strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL"><strong>رقم الفاكس:&nbsp; </strong>&nbsp;7662-205-11-966+</p><p dir="RTL"><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على:</strong> 2038222-11-966+،</p><p dir="RTL"><strong>وصلة هاتف:</strong>2340-2356-2317</p><p dir="RTL"><strong>مركز اتصال</strong><strong> </strong><strong>الهيئة العامة للغذاء والدواء</strong><strong> </strong><strong>: </strong>19999</p><p dir="RTL"><strong>البريد</strong><strong> الإلكتروني:</strong><strong> </strong><strong>&nbsp;</strong>npc.drug@sfda.gov.sa</p><p dir="RTL"><strong>الموقع</strong><strong> الإلكتروني: </strong>www.sfda.gov.sa/npc</p><p dir="RTL">&sect;&nbsp;&nbsp; <strong>دول</strong><strong> </strong><strong>مجلس</strong><strong> </strong><strong>التعاون</strong><strong> </strong><strong>الخليجي</strong><strong> </strong><strong>الأخرى</strong><strong>: </strong>يرجى الاتصال بالجهات المختصة ذات الصلة</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp; يجب عدم تناول <strong>لوماكس</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة أو الشريط.</p><p dir="RTL">-&nbsp; يحفظ في درجة حرارة أقل من 30 <sup>5</sup>م ، في مكان جاف، بعيداً عن الضوء.</p><p dir="RTL">-&nbsp; يجب عدم تناول <strong>لوماكس</strong> إذا لاحظت وجود أية علامات تلف واضحة.</p><p dir="RTL">-&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي كل قرص مكسو على:</p><p dir="RTL">المادة الفعالة: لوميفلوكساسين هيدروكلوريد بما يعادل لوميفلوكساسين 400 ملغم.</p><p dir="RTL">المواد الأخرى: لاكتوز أحادي الهيدرات،&nbsp; كربوكسي ميثيل سليلوز الكالسيوم، هيدروكسي بروبيل سليلوز، ستيرات بولي أوكسيل40، ستيرات المغنيسيوم، هيبروميلوز، بولي إثيلين جلايكول 6000، ثنائي أكسيد التيتانيوم وتلك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر <strong>لوماكس</strong> في عبوات تحتوي كلاً منها على 5 أو 10 أقراص في شريط واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الخليج للصناعات الدوائية &quot;جلفار&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            19/11/2020م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lomax 400mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains: 
Item No. 	Material Name	Scale (mg/Tab)
		
	Active Ingredient:	
1.		Lomefloxacin Hydrochloride 	450.600
	Equivalent to Lomefloxacin	400.000
		
	Inactive Ingredients:	
1.		Carboxy methyl cellulose calcium 	80.000
2.		Hydroxypropyl cellulose 	10.000
3.		Lactose monohydrate 	137.000
4.		Magnesium stearate 	5.000
5.		Polyoxyl 40 stearate 	2.000
6.		De-ionized water *	80.000
7.		Ethanol 95% *	60.000
		
	Coating Ingredients:	
1.		Hypromellose 	13.300
2.		Polyethylene glycol 6000	1.200
3.		Titanium dioxide 	2.600
4.		Talc fine powder 	2.000
5.		De-ionized water *	150.000
6.		Ethanol 95% *	100.000

* Evaporates during drying and coating process.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
Description: White to off-white, oblong, biconvex film-coated tablets may show specs on the surface. 
Marking: Face one: Embossed with “Lomax”
Face two: Score-line

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Treatment</u></p><p><strong>Lomax </strong>(lomefloxacin HCl) film-coated tablets are indicated for the treatment of adults with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:</p><p>(See&nbsp;Posology and method of administration&nbsp;for specific dosing recommendations.)</p><p>Lower Respiratory Tract</p><p><u>Acute Bacterial Exacerbation of Chronic Bronchitis</u>&nbsp;caused by&nbsp;<em>Haemophilus influenzae</em>&nbsp;or&nbsp;<em>Moraxella catarrhalis.</em><sup>1</sup></p><p><strong>Note:</strong><strong>&nbsp;</strong>Lomefloxacin is not indicated for the empiric treatment of acute bacterial exacerbation of chronic bronchitis when it is probable that&nbsp;<em>s pneumoniae</em>&nbsp;is a causative pathogen.&nbsp;<em>s pneumoniae</em>&nbsp;exhibits in vitro resistance to lomefloxacin, and the safety and efficacy of lomefloxacin in the treatment of patients with acute bacterial exacerbation of chronic bronchitis caused by&nbsp;<em>s pneumoniae</em>&nbsp;have not been demonstrated.</p><p>If lomefloxacin is to be prescribed for gram&ndash;stain&ndash;guided empiric therapy of acute bacterial exacerbation of chronic bronchitis, it should be used only if sputum gram stain demonstrates an adequate quality of specimen (&gt; 25 pmns/lpf) and there is both a predominance of gram-negative microorganisms and not a predominance of gram-positive microorganisms.</p><p><sup>1</sup>Although treatment of infections due to this microorganism in this organ system demonstrated a clinically acceptable overall outcome; efficacy was studied in fewer than 10 infections.</p><p><strong>Urinary Tract</strong></p><p><u>Uncomplicated Urinary Tract Infections</u>&nbsp;(cystitis) caused by&nbsp;<em>Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,</em>&nbsp;or&nbsp;<em>Staphylococcus saprophyticus. </em>(See Posology and method of administration, and&nbsp;Clinical studies - Uncomplicated cystitis<strong>). </strong></p><p><u>Complicated Urinary Tract Infections&nbsp;</u>caused by&nbsp;<em>Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Citrobacter diversus</em><sup>1</sup>&nbsp;or&nbsp;<em>Enterobacter cloacae</em>.<sup>1</sup></p><p><strong>Note:</strong>&nbsp;In clinical trials with patients experiencing complicated urinary tract infections (UTIs) due to&nbsp;<em>P aeruginosa,</em>&nbsp;12 of 16 patients had the microorganism eradicated from the urine after therapy with lomefloxacin. None of the patients had concomitant bacteremia. Serum levels of lomefloxacin do not reliably exceed the MIC of&nbsp;<em>Pseudomonas</em>&nbsp;isolates. The safety and efficacy of lomefloxacin in treating patients with&nbsp;<em>pseudomonas</em>&nbsp;bacteremia have not been established.</p><p>Appropriate culture and susceptibility tests should be performed before antimicrobial treatment in order to isolate and identify microorganisms causing infection and to determine their susceptibility to lomefloxacin. In patients with UTIs, therapy with lomefloxacin film-coated tablets may be initiated before results of these tests are known; once these results become available, appropriate therapy should be continued. In patients with an acute bacterial exacerbation of chronic bronchitis, therapy should not be started empirically with lomefloxacin when there is a probability the causative pathogen is&nbsp;<em>S pneumoniae.</em></p><p>Beta-lactamase production should have no effect on lomefloxacin activity.</p><p><strong><u>Prevention / prophylaxis</u></strong></p><p>Lomefloxacin is indicated preoperatively for the prevention of infection in the following situations:</p><p>&sect; Transrectal prostate biopsy: to reduce the incidence of urinary tract infection, in the early and late postoperative periods (3&ndash;5 days and 3&ndash;4 weeks post-surgery).</p><p>&sect; Transurethral surgical procedures: to reduce the incidence of urinary tract infection in the early postoperative period (3&ndash;5 days post-surgery).</p><p>Efficacy in decreasing the incidence of infections other than urinary tract infection has not been established. Lomefloxacin, like all drugs for prophylaxis of transurethral surgical procedures, usually should not be used in minor urologic procedures for which prophylaxis is not indicated (e.g., simple cystoscopy or retrograde pyelography). (See Posology and method of administration)</p><p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of lomefloxacin and other antibacterial drugs, lomefloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Lomax</strong> (lomefloxacin HCl) may be taken without regard to meals. Sucralfate and antacids containing magnesium or aluminium, or didanosine, chewable/buffered tablets or the paediatric powder for oral solution should not be taken within 4 hours before or 2 hours after taking lomefloxacin. Risk of reaction to solar UVA light may be reduced by taking lomefloxacin at least 12 hours before exposure to the sun (e.g., in the evening). (See&nbsp;Pharmacological properties).</p><p>See Therapeutic indications&nbsp;for information on appropriate pathogens and patient populations.</p><p><u>Treatment</u></p><p>Patients with normal renal function</p><p>The recommended daily dose of lomefloxacin is described in the following chart:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Unit Dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td><td style="vertical-align:top"><p><strong>Daily Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial exacerbation</p><p>of chronic bronchitis</p></td><td style="vertical-align:top"><p>400 mg</p></td><td style="vertical-align:top"><p>qd</p></td><td style="vertical-align:top"><p>10 days</p></td><td style="vertical-align:top"><p>400 mg</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis in females caused by&nbsp;<em>E coli</em></p></td><td style="vertical-align:top"><p>400 mg</p></td><td style="vertical-align:top"><p>qd</p></td><td style="vertical-align:top"><p>3 days</p></td><td style="vertical-align:top"><p>400 mg</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>(See&nbsp;Clinical studies - Uncomplicated cystitis.)</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis caused by&nbsp;<em>K pneumoniae, </em></p><p><em>P mirabilis,</em>&nbsp;or&nbsp;<em>S Saprophyticus</em></p></td><td style="vertical-align:top"><p>400 mg</p></td><td style="vertical-align:top"><p>qd</p></td><td style="vertical-align:top"><p>10 days</p></td><td style="vertical-align:top"><p>400 mg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated UTI</p></td><td style="vertical-align:top"><p>400 mg</p></td><td style="vertical-align:top"><p>qd</p></td><td style="vertical-align:top"><p>14 days</p></td><td style="vertical-align:top"><p>400 mg</p></td></tr></tbody></table><p>Elderly patients</p><p>No dosage adjustment is needed for elderly patients with normal renal function (ClCr&ge; 40 mL/min/1.73 m2).</p><p>Patients with impaired renal function</p><p>Lomefloxacin is primarily eliminated by renal excretion. (See Pharmacological properties). Modification of dosage is recommended in patients with renal dysfunction. In patients with a creatinine clearance &gt; 10 mL/min/1.73 m2&nbsp;but</p><p>&nbsp;&lt; 40 mL/min/1.73 m2, the recommended dosage is an initial loading dose of 400 mg followed by daily maintenance doses of 200 mg (1/2 tablet) once daily for the duration of treatment. It is suggested that serial determinations of lomefloxacin levels be performed to determine any necessary alteration in the appropriate next dosing interval.</p><p>If only the serum creatinine is known, the following formula may be used to estimate creatinine clearance.</p><p>&nbsp;</p><p>Men:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(weight in kg) &times; (140 &ndash; age)</u>&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(72) &times; serum creatinine (mg/dL)</p><p>&nbsp;</p><p>Women:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0.85) &times; (calculated value for men)</p><p>&nbsp;</p><p>Dialysis patients</p><p>Hemodialysis removes only a negligible amount of lomefloxacin (3% in 4 hours). Hemodialysis patients should receive an initial loading dose of 400 mg followed by daily maintenance doses of 200 mg (1/2 tablet) once daily for the duration of treatment.</p><p>Patients with cirrhosis</p><p>Cirrhosis does not reduce the nonrenal clearance of lomefloxacin. The need for a dosage reduction in this population should be based on the degree of renal function of the patient and on the plasma concentrations. (See&nbsp;Pharmacological properties&nbsp;and&nbsp; Posology and method of administration - Patients with impaired renal function.)</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Prevention / prophylaxis</u></strong></p><p>The recommended dose of lomefloxacin is described in the following chart:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Procedure</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Oral Administration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Transrectal prostate biopsy</p></td><td style="vertical-align:top"><p>400mg single dose</p></td><td style="vertical-align:top"><p>1&ndash;6 hours prior to procedure</p></td></tr><tr><td style="vertical-align:top"><p>Transurethral surgical procedures*</p></td><td style="vertical-align:top"><p>400mg single dose</p></td><td style="vertical-align:top"><p>2&ndash;6 hours prior to procedure</p></td></tr></tbody></table><p>* When preoperative prophylaxis is considered appropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lomefloxacin is contraindicated in persons with a history of hypersensitivity to lomefloxacin or any member of the quinolone group of antimicrobial agents.
Fluoroquinolone antibiotics (such as Lomefloxacin) should not be used:
	To treat infections that might get better without treatment or are not severe (such as throat infections);
	To treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis;
	For preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder);
	To treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used.
Fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.
Fluoroquinolones should be used with special caution in the elderly, patients with kidney disease and those who have had organ transplantation because these patients are at a higher risk of tendon injury. Since the use of a corticosteroid with a Fluoroquinolone also increases this risk, combined use of these medicines should be avoided.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Warnings</u></strong></p><p><strong>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence</strong></p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after a careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or vascular Ehlers-Danlos syndrome, Turner syndrome, Beh&ccedil;et&acute;s disease, hypertension, rheumatoid arthritis) or additionally</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&rsquo;s syndrome) or additionally</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for heart valve regurgitation/incompetence (e.g. infective endocarditis).</p><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p><p><strong>Photosensitivity</strong></p><p>Moderate to severe phototoxic reactions have occurred in patients exposed to direct or indirect sunlight or to artificial ultraviolet light (e.g., sunlamps) during or following treatment with lomefloxacin. These reactions have also occurred in patients exposed to shaded or diffuse light, including exposure through glass. Patients should be advised to discontinue lomefloxacin therapy at the first signs or symptoms of a phototoxicity reaction such as a sensation of skin burning, redness, swelling, blisters, rash, itching, or dermatitis.</p><p>These phototoxic reactions have occurred with and without the use of sunscreens or sunblocks. Single doses of lomefloxacin have been associated with these types of reactions. In a few cases, recovery was prolonged for several weeks. As with some other types of phototoxicity, there is the potential for exacerbation of the reaction on re-exposure to sunlight or artificial ultraviolet light prior to complete recovery from the reaction. In rare cases, reactions have recurred up to several weeks after stopping lomefloxacin therapy.</p><p>Exposure to direct or indirect sunlight (even when using sunscreens or sunblocks) should be avoided while taking lomefloxacin and for several days following therapy. Lomefloxacin therapy should be discontinued immediately at the first signs or symptoms of phototoxicity. Risk of phototoxicity may be reduced by taking lomefloxacin in the evening (see&nbsp;Posology and method of administration.)</p><p>The safety and efficacy of lomefloxacin in paediatric patients and adolescents (under the age of 18 years), pregnant women, and lactating women have not been established. (See&nbsp;precautions - paediatric use, and Pregnancy and lactation).&nbsp;</p><p>The oral administration of multiple doses of lomefloxacin to juvenile dogs at 0.3 times and to rats at 5.4 times the recommended adult human dose based on mg/m2&nbsp;(0.6 and 34 times the recommended adult human dose based on mg/kg, respectively) caused arthropathy and lameness. Histopathologic examination of the weight-bearing joints of these animals revealed permanent lesions of the cartilage. Other quinolones also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in juvenile animals of various species. (See&nbsp;animal pharmacology.)</p><p><strong>Convulsions have been reported in patients receiving lomefloxacin</strong></p><p>Whether the convulsions were directly related to lomefloxacin administration has not yet been established. However, convulsions, increased intracranial pressure, and toxic psychoses have been reported in patients receiving other quinolones. Nevertheless, lomefloxacin has been associated with a possible increased risk of seizures compared to other quinolones. Some of these may occur with a relative absence of predisposing factors. Quinolones may also cause central nervous system (CNS) stimulation, which may lead to tremors, restlessness, light-headedness, confusion, and hallucinations. If any of these reactions occurs in patients receiving lomefloxacin, the drug should be discontinued and appropriate measures instituted. However, until more information becomes available, lomefloxacin, like all other quinolones, should be used with caution in patients with known or suspected CNS disorders, such as severe cerebral arteriosclerosis, epilepsy, or other factors that predispose to seizures (See&nbsp;Undesirable Effects.) Psychiatric disturbances, agitation, anxiety, and sleep disorders may be more common with lomefloxacin than other products in the quinolone class.</p><p>The safety and efficacy of lomefloxacin in the treatment of acute bacterial exacerbation of chronic bronchitis due to&nbsp;<em>S pneumoniae</em>&nbsp;have not been demonstrated. This product should not be used empirically in the treatment of acute bacterial exacerbation of chronic bronchitis when it is probable that&nbsp;<em>S pneumoniae</em>&nbsp;is a causative pathogen.</p><p>In clinical trials of complicated UTIs due to&nbsp;<em>P aeruginosa,</em>&nbsp;12 of 16 patients had the microorganism eradicated from the urine after therapy with lomefloxacin. No patients had concomitant bacteremia. Serum levels of lomefloxacin do not reliably exceed the MIC of&nbsp;<em>Pseudomonas</em>&nbsp;isolates. The safety and efficacy of lomefloxacin in treating patients with&nbsp;<em>pseudomonas</em>&nbsp;bacteremia have not been established.</p><p>Serious and occasionally fatal hypersensitivity (anaphylactoid or anaphylactic) reactions, some following the first dose, have been reported in patients receiving quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial oedema, dyspnoea, urticaria, or itching. Only a few of these patients had a history of previous hypersensitivity reactions. Serious hypersensitivity reactions have also been reported following treatment with lomefloxacin. If an allergic reaction to lomefloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment with epinephrine. Oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, including intubation, should be administered as indicated.</p><p><strong>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including lomefloxacin, and may range from mild to life-threatening in severity. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial agents.</strong>&nbsp;Treatment with antimicrobial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by&nbsp;<em>Clostridium difficile</em>&nbsp;is a primary cause of &quot;antibiotic-associated colitis.&quot; After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against&nbsp;<em>C difficile</em>&nbsp;colitis.</p><p><strong>QT interval prolongation/torsades de pointes</strong></p><p>Rare cases of torsades de pointes have been spontaneously reported during post-marketing surveillance in patients receiving quinolones, including lomefloxacin. These rare cases were associated with one or more of the following factors: age over 60, female gender, underlying cardiac disease, and/or use of multiple medications. Lomefloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving class IA (quinidine, procainamide), or class III (amiodarone, sotalol) antiarrhythmic agents.</p><p><strong>Peripheral neuropathy</strong></p><p>Rare cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving quinolones, including lomefloxacin. Lomefloxacin should be discontinued if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness, or is found to have deficits in light touch, pain, temperature, position sense, vibratory sensation, and/or motor strength in order to prevent the development of an irreversible condition.</p><p><strong>Tendon effects</strong></p><p>Ruptures of the shoulder, hand, Achilles tendon or other tendons that required surgical repair or resulted in prolonged disability have been reported in patients receiving quinolones, including lomefloxacin. Post-marketing surveillance reports indicate that this risk may be increased in patients receiving concomitant corticosteroids, especially the elderly. Lomefloxacin should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon. Patients should rest and refrain from exercise until the diagnosis of tendonitis or tendon rupture has been excluded. Tendon rupture can occur during or after therapy with quinolones, including lomefloxacin.</p><p><strong><u>Precautions</u></strong></p><p><strong>General</strong></p><p>Alteration of the dosage regimen is recommended for patients with impairment of renal function (ClCr&lt; 40 mL/min/1.73 m2). (See&nbsp;Posology and method of administration).</p><p>Prescribing lomefloxacin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p><p><strong>Paediatric use</strong></p><p>The safety and effectiveness of lomefloxacin in paediatric patients and adolescents less than 18 years of age have not been established. Lomefloxacin causes arthropathy in juvenile animals of several species. (See Special warnings and precautions for use&nbsp;and&nbsp;animal pharmacology.)</p><p><strong>Geriatric use</strong></p><p>Of the total number of subjects in clinical studies of lomefloxacin, 25% were &ge; 65 years and 9% were &ge; 75 years. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p><p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See&nbsp;Pharmacological properties - pharmacokinetics in the geriatric population.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Theophylline</p><p>In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin. In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance. Though individual theophylline levels fluctuated, there were no clinically significant symptoms of drug interaction.</p><p>Antacids and sucralfate</p><p>Sucralfate and antacids containing magnesium or aluminium, as well as formulations containing divalent and trivalent cations such as didanosine, chewable/buffered tablets or the paediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability. Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean Cmax&nbsp;decreased by 30% and mean Tmax&nbsp;increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%). Magnesium- and aluminium-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin. Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability; therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.</p><p>Caffeine</p><p>Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd. This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine. No data are available on potential interactions in individuals who consume greater than 200 mg of caffeine per day or in those, such as the geriatric population, who are generally believed to be more susceptible to the development of drug-induced CNS-related adverse effects. Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.</p><p>Cimetidine</p><p>Cimetidine has been demonstrated to interfere with the elimination of other quinolones. This interference has resulted in significant increases in half-life and AUC. The interaction between lomefloxacin and cimetidine has not been studied.</p><p>Cyclosporine</p><p>Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class. Interaction between lomefloxacin and cyclosporine has not been studied.</p><p>Omeprazole</p><p>No clinically significant changes in lomefloxacin pharmacokinetics (AUC, Cmax,&nbsp;or Tmax) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers. Changes in omeprazole pharmacokinetics were not studied.</p><p>Phenytoin</p><p>No significant differences were observed in mean phenytoin AUC, Cmax, Cmin&nbsp;or Tmax&nbsp;(although Cmax increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were co-administered with lomefloxacin (400 mg qd) for five days in 15 healthy males. Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.</p><p>Probenecid</p><p>Probenecid slows the renal elimination of lomefloxacin. An increase of 63% in the mean AUC and increases of 50% and 4%, respectively, in the mean Tmax&nbsp;and mean Cmax&nbsp;were noted in 1 study of 6 individuals.</p><p>Terfenadine</p><p>No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.</p><p>Warfarin</p><p>Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives. When these products are administered concomitantly, prothrombin or other suitable coagulation tests should be monitored closely. However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p><strong>Teratogenic effects: Pregnancy Category C</strong></p><p>Reproductive function studies have been performed in rats at doses up to 8 times the recommended human dose based on mg/m2&nbsp;(34 times the recommended human dose based on mg/kg), and no impaired fertility or harm to the foetus was reported due to lomefloxacin. Increased incidence of foetal loss in monkeys has been observed at approximately 3 to 6 times the recommended human dose based on mg/m2&nbsp;(6 to 12 times the recommended human dose based on mg/kg). No teratogenicity has been observed in rats and monkeys at up to 16 times the recommended human dose exposure. In the rabbit, maternal toxicity and associated fetotoxicity, decreased placental weight, and variations of the coccygeal vertebrae occurred at doses 2 times the recommended human exposure based on mg/m2. There are, however, no adequate and well-controlled studies in pregnant women. Lomefloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p><strong><u>Nursing mothers</u></strong></p><p>It is not known whether lomefloxacin is excreted in human milk. However, it is known that other drugs of this class are excreted in human milk and that lomefloxacin is excreted in the milk of lactating rats. Because of the potential for serious adverse reactions from lomefloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lomefloxacin can cause dizziness and light-headedness and, therefore, patients should know how they react to lomefloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials, most of the adverse events reported were mild to moderate in severity and transient in nature. During these clinical investigations, 5,623 patients received lomefloxacin. In 2.2% of the patients, lomefloxacin was discontinued because of adverse events, primarily involving the gastrointestinal system (0.7%), skin (0.7%), or CNS (0.5%).</p><p><u>Adverse clinical events</u></p><p>The events with the highest incidence (&ge; 1%) in patients, regardless of relationship to drug, were headache (3.6%), nausea (3.5%), and photosensitivity (2.3%) [See Special warnings and precautions for use], dizziness (2.1%), diarrhoea (1.4%), and abdominal pain (1.2%).</p><p>Additional clinical events reported in &lt; 1% of patients treated with lomefloxacin, regardless of relationship to drug, are listed below:</p><p><strong>Autonomic:</strong><strong>&nbsp;</strong>increased sweating, dry mouth, flushing, syncope.</p><p><strong>Body as a whole*:</strong><strong>&nbsp;</strong>fatigue, back pain, malaise, asthenia, chest pain, face edema, hot flashes, influenza-like symptoms, edema, chills, allergic reaction, anaphylactoid reaction, decreased heat tolerance.</p><p><strong>Cardiovascular**:</strong><strong>&nbsp;</strong>tachycardia, hypertension, hypotension, myocardial infarction, angina pectoris, cardiac failure, bradycardia, arrhythmia, phlebitis, pulmonary embolism, extrasystoles, cerebrovascular disorder, cyanosis, cardiomyopathy.</p><p><strong>Central and peripheral nervous system*:</strong><strong>&nbsp;</strong>tremor, vertigo, paresthesias, twitching, hypertonia, convulsions, hyperkinesia, coma.</p><p><strong>Gastrointestinal:</strong><strong>&nbsp;</strong>dyspepsia, vomiting, flatulence, constipation, gastrointestinal bleeding, dysphagia, stomatitis, tongue discoloration, gastrointestinal inflammation.</p><p><strong>Hearing*:</strong><strong>&nbsp;</strong>earache, tinnitus.</p><p><strong>Hematologic:</strong>&nbsp;purpura, lymphadenopathy, thrombocythemia, anemia, thrombocytopenia, increased fibrinolysis.</p><p><strong>Hepatic:</strong><strong>&nbsp;</strong>abnormal liver function.</p><p><strong>Metabolic:</strong><strong>&nbsp;</strong>thirst, hyperglycemia, hypoglycemia, gout.</p><p><strong>Musculoskeletal*:</strong><strong>&nbsp;</strong>arthralgia, myalgia, leg cramps.</p><p><strong>Ophthalmologic*:</strong><strong>&nbsp;</strong>abnormal vision, conjunctivitis, photophobia, eye pain, abnormal lacrimation.</p><p><strong>Psychiatric*:</strong><strong>&nbsp;</strong>insomnia, nervousness, somnolence, anorexia, depression, confusion, agitation, increased appetite, depersonalization, paranoid reaction, anxiety, paroniria, abnormal thinking, concentration impairment.</p><p><strong>Reproductive system:</strong><strong>&nbsp;</strong>Female: vaginal moniliasis, vaginitis, leukorrhea, menstrual disorder, perineal pain, intermenstrual bleeding. Male: epididymitis, orchitis.</p><p><strong>Resistance mechanism:</strong><strong>&nbsp;</strong>viral infection, moniliasis, fungal infection.</p><p><strong>Respiratory:</strong><strong>&nbsp;</strong>respiratory infection, rhinitis, pharyngitis, dyspnea, cough, epistaxis, bronchospasm, respiratory disorder, increased sputum, stridor, respiratory depression.</p><p><strong>Skin/Allergic:</strong><strong>&nbsp;</strong>pruritus, rash, urticaria, skin exfoliation, bullous eruption, eczema, skin disorder, acne, skin discoloration, skin ulceration, angioedema. (See also&nbsp;body as a whole<em>.</em>)</p><p>&nbsp;</p><p><strong>Special senses:</strong><strong>&nbsp;</strong>taste perversion.</p><p><strong>Urinary:</strong><strong>&nbsp;</strong>hematuria, micturition disorder, dysuria, strangury, anuria.</p><p>* Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).</p><p>** Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).</p><p><u>Adverse laboratory events</u></p><p>Changes in laboratory parameters, listed as adverse events, without regard to drug relationship include:</p><p><strong>Hematologic:</strong><strong>&nbsp;</strong>monocytosis (0.2%), eosinophilia (0.1%), leukopenia (0.1%), leukocytosis (0.1%).</p><p><strong>Renal:</strong>&nbsp;elevated BUN (0.1%), decreased potassium (0.1%), increased creatinine (0.1%).</p><p><strong>Hepatic:</strong><strong>&nbsp;</strong>elevations of ALT (SGPT) (0.4%), AST (SGOT) (0.3%), bilirubin (0.1%), alkaline phosphatase (0.1%).</p><p>Additional laboratory changes occurring in &lt; 0.1% in the clinical studies included: elevation of serum gamma glutamyl transferase, decrease in total protein or albumin, prolongation of prothrombin time, anemia, decrease in hemoglobin, thrombocythemia, thrombocytopenia, abnormalities of urine specific gravity or serum electrolytes, increased albumin, elevated ESR, albuminuria, macrocytosis.</p><p><u>Post-Marketing Adverse Events</u></p><p>Adverse events reported from worldwide marketing experience with lomefloxacin are: anaphylaxis, cardiopulmonary arrest, laryngeal or pulmonary oedema, ataxia, cerebral thrombosis, hallucinations, painful oral mucosa, pseudomembranous colitis, hemolytic anaemia, hepatitis, tendinitis, diplopia, photophobia, phobia, exfoliative dermatitis, hyperpigmentation, Stevens-Johnson syndrome, toxic epidermal necrolysis, dysgeusia, interstitial nephritis, polyuria, renal failure, urinary retention, and vasculitis.</p><p><u>Quinolone-class adverse events</u></p><p>Additional quinolone-class adverse events include: peripheral neuropathy, torsades de pointes, erythema nodosum, hepatic necrosis, possible exacerbation of myasthenia gravis, dysphasia, nystagmus, intestinal perforation, manic reaction, renal calculi, acidosis and hiccough.</p><p><strong>Laboratory adverse events include: </strong>agranulocytosis, elevation of serum triglycerides, elevation of serum cholesterol, elevation of blood glucose, elevation of serum potassium, albuminuria, candiduria, and crystalluria.</p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC at </strong>+966-11-2038222, <strong>Exts: </strong>2317-2356-2340</p><p><strong>SFDA Call Centre: </strong>19999</p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p><p>&sect; <strong>Other GCC States: </strong>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on overdosage in humans is limited. In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage, and the patient should be carefully observed and given supportive treatment. Adequate hydration must be maintained. Hemodialysis or peritoneal dialysis is unlikely to aid in the removal of lomefloxacin as &lt; 3% is removed by these modalities.</p><p>Clinical signs of acute toxicity in rodents progressed from salivation to tremors, decreased activity, dyspnea, and clonic convulsions prior to death. These signs were noted in rats and mice as lomefloxacin doses were increased.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Lomax</strong> (lomefloxacin HCl) is a synthetic broad-spectrum antimicrobial agent for oral administration. Lomefloxacin HCl, a difluoroquinolone, is the monohydrochloride salt of (&plusmn;)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid.&nbsp;</p><p><u>Microbiology</u></p><p>Lomefloxacin is a bactericidal agent with in vitro activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzyme DNA gyrase, which is needed for the transcription and replication of bacterial DNA. The minimum bactericidal concentration (MBC) generally does not exceed the minimum inhibitory concentration (MIC) by more than a factor of 2, except for staphylococci, which usually have MBCs 2 to 4 times the MIC.</p><p>Lomefloxacin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (See Therapeutic indications)</p><p><strong>Gram-positive aerobes</strong></p><p>&nbsp;<em>Staphylococcus saprophyticus</em></p><p><strong>Gram-negative aerobes</strong></p><p>&nbsp;<em>Citrobacter diversus</em></p><p>&nbsp;<em>Enterobacter cloacae</em></p><p>&nbsp;<em>Escherichia coli</em></p><p>&nbsp;<em>Haemophilus influenzae</em></p><p>&nbsp;<em>Klebsiella pneumoniae</em></p><p>&nbsp;<em>Moraxella catarrhalis</em></p><p>&nbsp;<em>Proteus mirabilis</em></p><p>&nbsp;<em>Pseudomonas aeruginosa</em>&nbsp;(urinary tract only&mdash;See&nbsp;Therapeutic indications&nbsp;and Special warnings and precautions for use).</p><p>The following in vitro data are available; however, their clinical significance is unknown.</p><p>Lomefloxacin exhibits in vitro MICs of 2 &micro;g/mL or less against most strains of the following organisms; however, the safety and effectiveness of lomefloxacin in treating clinical infections due to these organisms have not been established in adequate and well-controlled trials:</p><p><strong>Gram-positive aerobes</strong></p><p>&nbsp;<em>Staphylococcus aureus</em>&nbsp;(including methicillin-resistant strains)</p><p>&nbsp;<em>Staphylococcus epidermidis&nbsp;</em>(including methicillin-resistant strains)</p><p><strong>Gram-negative aerobes</strong></p><p>&nbsp;<em>Aeromonas hydrophila</em></p><p>&nbsp;<em>Citrobacter freundii</em></p><p>&nbsp;<em>Enterobacter aerogenes</em></p><p>&nbsp;<em>Enterobacter agglomerans</em></p><p>&nbsp;<em>Haemophilus parainfluenzae</em></p><p>&nbsp;<em>Hafnia alvei</em></p><p>&nbsp;<em>Klebsiella oxytoca</em></p><p>&nbsp;<em>Klebsiella ozaenae</em></p><p>&nbsp;<em>Morganella morganii</em></p><p>&nbsp;<em>Proteus vulgaris</em></p><p>&nbsp;<em>Providencia alcalifaciens</em></p><p>&nbsp;<em>Providencia rettgeri</em></p><p>&nbsp;<em>Serratia liquefaciens</em></p><p>&nbsp;<em>Serratia marcescens</em></p><p><strong>Other organisms</strong></p><p>&nbsp;<em>Legionella pneumophila</em></p><p>Beta-lactamase production should have no effect on the in vitro activity of lomefloxacin.</p><p>Most group A, B, D, and G streptococci,&nbsp;<em>Streptococcus pneumoniae, Pseudomonas cepacia, Ureaplasma urealyticum, Mycoplasma hominis,</em>&nbsp;and anaerobic bacteria are resistant to lomefloxacin.</p><p>Lomefloxacin appears slightly less active in vitro when tested at acidic pH. An increase in inoculum size has little effect on the in vitro activity of lomefloxacin. In vitro resistance to lomefloxacin develops slowly (multiple-step mutation). Rapid one-step development of resistance occurs only rarely (&lt; 10&ndash;9) in vitro.</p><p>Cross-resistance between lomefloxacin and other quinolone-class antimicrobial agents has been reported; however, cross-resistance between lomefloxacin and members of other classes of antimicrobial agents, such as aminoglycosides, penicillins, tetracyclines, cephalosporins, or sulfonamides has not yet been reported. Lomefloxacin is active in vitro against some strains of cephalosporin- and aminoglycoside-resistant gram-negative bacteria.</p><p><u>Susceptibility tests</u></p><p>Diffusion techniques</p><p>Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents. One such standardized procedure1&nbsp;that has been recommended for use with disks to test the susceptibility of organisms to lomefloxacin uses the 10-&micro;g lomefloxacin disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for lomefloxacin.</p><p>Reports from the laboratory giving results of the standard single-disk susceptibility test with a 10-&micro;g lomefloxacin disk should be interpreted according to the following criteria:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Zone Diameter (mm)</strong></p></td><td style="vertical-align:top"><p><strong>Interpretation</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 22</p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td></tr><tr><td style="vertical-align:top"><p>19&ndash;21</p></td><td style="vertical-align:top"><p>Intermediate (I)</p></td></tr><tr><td style="vertical-align:top"><p>&le; 18</p></td><td style="vertical-align:top"><p>Resistant (R)</p></td></tr></tbody></table><p>A report of &quot;susceptible&quot; indicates that the pathogen is likely to be inhibited by generally achievable drug concentrations. A report of &quot;intermediate&quot; indicates that the result should be considered equivocal, and, if the organism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &quot;resistant&quot; indicates that achievable drug concentrations are unlikely to be inhibitory, and other therapy should be selected.</p><p>Standardized susceptibility test procedures require the use of laboratory control organisms. The 10-&micro;g lomefloxacin disk should give the following zone diameters:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td style="vertical-align:top"><p><strong>Zone Diameter (mm)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>S aureus</em>&nbsp;(ATCC 25923)</p></td><td style="vertical-align:top"><p>23&ndash;29</p></td></tr><tr><td style="vertical-align:top"><p><em>E coli</em>&nbsp;(ATCC 25922)</p></td><td style="vertical-align:top"><p>27&ndash;33</p></td></tr><tr><td style="vertical-align:top"><p><em>P aeruginosa</em>&nbsp;(ATCC 27853)</p></td><td style="vertical-align:top"><p>22&ndash;28</p></td></tr></tbody></table><p>Dilution techniques</p><p>Use a standardized dilution method2&nbsp;(broth, agar, or microdilution) or equivalent with lomefloxacin powder. The MIC values obtained should be interpreted according to the following criteria:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>MIC (&micro;g/mL)</strong></p></td><td style="vertical-align:top"><p><strong>Interpretation</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&le;</strong>&nbsp;2</p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>Intermediate (I)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 8</p></td><td style="vertical-align:top"><p>Resistant (R)</p></td></tr></tbody></table><p>As with standard diffusion techniques, dilution methods require the use of laboratory control organisms. Standard lomefloxacin powder should provide the following MIC values:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td style="vertical-align:top"><p><strong>MIC (&micro;g/mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>S aureus</em>&nbsp;(ATCC 29213)</p></td><td style="vertical-align:top"><p>0.25&ndash;2.0</p></td></tr><tr><td style="vertical-align:top"><p><em>E coli</em>&nbsp;(ATCC 25922)</p></td><td style="vertical-align:top"><p>0.03&ndash;0.12</p></td></tr><tr><td style="vertical-align:top"><p><em>P aeruginosa</em>&nbsp;(ATCC 27853)</p></td><td style="vertical-align:top"><p>1.0&ndash;4.0</p></td></tr></tbody></table><p><strong>Clinical studies - uncomplicated cystitis</strong></p><p>In three controlled clinical studies of uncomplicated cystitis in females, two performed in the United States and one in Canada, lomefloxacin was compared to other oral antimicrobial agents. In these studies, using very strict evaluability criteria and microbiological criteria at 5&ndash;9 days posttherapy follow-up, the following bacterial eradication outcomes were obtained:</p><p>Studies 1, 2, and 3</p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td colspan="5" style="vertical-align:top"><p>U.S. AND CANADIAN STUDIES</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Lomefloxacin<br />3-Day Treatment</p></td><td style="vertical-align:top"><p>Norfloxacin<br />3-Day Treatment</p></td><td style="vertical-align:top"><p>Ofloxacin<br />3-Day Treatment</p></td><td style="vertical-align:top"><p>Trimethoprim/<br />sulfamethoxazole<br />10-Day Treatment</p></td></tr><tr><td style="vertical-align:top"><p><em>E coli</em></p></td><td style="vertical-align:top"><p>133/135 (99%)</p></td><td style="vertical-align:top"><p>36/39 (92%)</p></td><td style="vertical-align:top"><p>65/67 (97%)</p></td><td style="vertical-align:top"><p>33/34 (97%)</p></td></tr><tr><td style="vertical-align:top"><p><em>K pneumoniae</em></p></td><td style="vertical-align:top"><p>7/7 (100%)</p></td><td style="vertical-align:top"><p>2/2 (100%)</p></td><td style="vertical-align:top"><p>4/4 (100%)</p></td><td style="vertical-align:top"><p>2/2 (100%)</p></td></tr><tr><td style="vertical-align:top"><p><em>P mirabilis</em></p></td><td style="vertical-align:top"><p>8/8 (100%)</p></td><td style="vertical-align:top"><p>1/1 (100%)</p></td><td style="vertical-align:top"><p>2/2 (100%)</p></td><td style="vertical-align:top"><p>1/1 (100%)</p></td></tr><tr><td style="vertical-align:top"><p><em>S saprophyticus</em></p></td><td style="vertical-align:top"><p>11/11 (100%)</p></td><td style="vertical-align:top"><p>3/3 (100%)</p></td><td style="vertical-align:top"><p>1/1 (100%)</p></td><td style="vertical-align:top"><p>0/0</p></td></tr></tbody></table><p>Study 4</p><p>In a controlled clinical study of uncomplicated cystitis performed in Sweden, lomefloxacin 3-day treatment was compared with lomefloxacin 7-day treatment and norfloxacin 7-day treatment. In this study, using very strict evaluability criteria and microbiological criteria at 5&ndash;9 days post-therapy follow-up, the following bacterial eradication outcomes were obtained:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="4" style="vertical-align:top"><p>SWEDISH STUDY</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Lomefloxacin<br />3-Day Treatment</p></td><td style="vertical-align:top"><p>Lomefloxacin<br />7-Day Treatment</p></td><td style="vertical-align:top"><p>Norfloxacin<br />7-Day Treatment</p></td></tr><tr><td style="vertical-align:top"><p><em>E coli</em></p></td><td style="vertical-align:top"><p>101/109 (93%)</p></td><td style="vertical-align:top"><p>102/104 (98%)</p></td><td style="vertical-align:top"><p>108/110 (98%)</p></td></tr><tr><td style="vertical-align:top"><p><em>K pneumoniae</em></p></td><td style="vertical-align:top"><p>2/2 (100%)</p></td><td style="vertical-align:top"><p>5/5 (100%)</p></td><td style="vertical-align:top"><p>1/1 (100%)</p></td></tr><tr><td style="vertical-align:top"><p><em>P mirabilis</em></p></td><td style="vertical-align:top"><p>0/0</p></td><td style="vertical-align:top"><p>6/6 (100%)</p></td><td style="vertical-align:top"><p>4/4 (100%)</p></td></tr><tr><td style="vertical-align:top"><p><em>S saprophyticus</em></p></td><td style="vertical-align:top"><p>11/17 (65%)</p></td><td style="vertical-align:top"><p>23/23 (100%)</p></td><td style="vertical-align:top"><p>16/16 (100%)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics in healthy volunteers</p><p>In 6 fasting healthy male volunteers, approximately 95% to 98% of a single oral dose of lomefloxacin was absorbed. Absorption was rapid following single doses of 200 and 400mg (Tmax&nbsp;0.8 to 1.4 hours). Mean plasma concentration increased proportionally between 100 and 400 mg as shown below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose (mg)</strong></p></td><td style="vertical-align:top"><p><strong>Mean Peak Plasma Concentration<br />(&micro;g/mL)</strong></p></td><td style="vertical-align:top"><p><strong>Area Under Curve (AUC)<br />(&micro;g∙h/mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>5.6</p></td></tr><tr><td style="vertical-align:top"><p>200</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>10.9</p></td></tr><tr><td style="vertical-align:top"><p>400</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>26.1</p></td></tr></tbody></table><p>In 6 healthy male volunteers administered 400 mg of lomefloxacin on an empty stomach qd for 7 days, the following mean pharmacokinetic parameter values were obtained:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>2.8 &micro;g/mL</p></td></tr><tr><td style="vertical-align:top"><p>Cmin</p></td><td style="vertical-align:top"><p>0.27 &micro;g/mL</p></td></tr><tr><td style="vertical-align:top"><p>AUC0&ndash;24 h</p></td><td style="vertical-align:top"><p>25.9 &micro;g∙h/mL</p></td></tr><tr><td style="vertical-align:top"><p>Tmax</p></td><td style="vertical-align:top"><p>1.5 h</p></td></tr><tr><td style="vertical-align:top"><p>t1/2</p></td><td style="vertical-align:top"><p>7.75 h</p></td></tr></tbody></table><p>The elimination half-life in 8 subjects with normal renal function was approximately 8 hours. At 24 hours post dose, subjects with normal renal function receiving single doses of 200 or 400 mg had mean plasma lomefloxacin concentrations of 0.10 and 0.24 &micro;g/mL, respectively. Steady-state concentrations were achieved within 48 hours of initiating therapy with one-a-day dosing. There was no drug accumulation with single-daily dosing in patients with normal renal function.</p><p>Approximately 65% of an orally administered dose was excreted in the urine as unchanged drug in patients with normal renal function. Following a 400-mg dose of lomefloxacin administered qd for 7 days, the mean urine concentration 4 hours post dose was in excess of 300 &micro;g/mL. The mean urine concentration exceeded 35 &micro;g/mL for at least 24 hours after dosing.</p><p>Following a single 400-mg dose, the solubility of lomefloxacin in urine usually exceeded its peak urinary concentration 2- to 6-fold. In this study, urine pH affected the solubility of lomefloxacin with solubilities ranging from 7.8 mg/mL at pH 5.2, to 2.4 mg/mL at pH 6.5, and 3.03 mg/mL at pH 8.12.</p><p>The urinary excretion of lomefloxacin was virtually complete within 72 hours after cessation of dosing, with approximately 65% of the dose being recovered as parent drug and 9% as its glucuronide metabolite. The mean renal clearance was 145 mL/min in subjects with normal renal function (GFR = 120 mL/min). This may indicate tubular secretion.</p><p><strong>Food effect</strong></p><p>When lomefloxacin and food were administered concomitantly, the rate of drug absorption was delayed (Tmax&nbsp;increased to 2 hours [delayed by 41%], Cmax&nbsp;decreased by 18%), and the extent of absorption (AUC) was decreased by 12%.</p><p><strong>Pharmacokinetics in the geriatric population</strong></p><p>In 16 healthy elderly volunteers (61 to 76 years of age) with normal renal function for their age, the half-life of lomefloxacin (mean of 8 hours) and its peak plasma concentration (mean of 4.2 &micro;g/mL) following a single 400-mg dose were similar to those in 8 younger subjects dosed with a single 400-mg dose. Thus, drug absorption appears unaffected in the elderly. Plasma clearance was, however, reduced in this elderly population by approximately 25%, and the AUC was increased by approximately 33%. This slower elimination most likely reflects the decreased renal function normally observed in the geriatric population.</p><p><strong>Pharmacokinetics in renally impaired patients</strong></p><p>In 8 patients with creatinine clearance (ClCr) between 10 and 40 mL/min/1.73 m2, the mean AUC after a single 400-mg dose of lomefloxacin increased 335% over the AUC demonstrated in patients with a ClCr&gt; 80 mL/min/1.73 m2. Also, in these patients, the mean t1/2&nbsp;increased to 21 hours. In 8 patients with ClCr&lt; 10 mL/min/1.73 m2, the mean AUC after a single 400-mg dose of lomefloxacin increased 700% over the AUC demonstrated in patients with a ClCr&gt; 80 mL/min/1.73 m2. In these patients with ClCr&lt; 10 mL/min/1.73 m2, the mean t1/2&nbsp;increased to 45 hours. The plasma clearance of lomefloxacin was closely correlated with creatinine clearance, ranging from 31 mL/min/1.73 m2&nbsp;when creatinine clearance was zero to 271 mL/min/1.73 m2&nbsp;at a normal creatinine clearance of 110 mL/min/1.73 m2. Peak lomefloxacin concentrations were not affected by the degree of renal function when single doses of lomefloxacin were administered. Adjustment of dosage schedules for patients with such decreases in renal function is warranted. (See posology and method of administration).</p><p><strong>Pharmacokinetics in patients with cirrhosis</strong></p><p>In 12 patients with histologically confirmed cirrhosis, no significant changes in rate or extent of lomefloxacin exposure (Cmax, Tmax, t1/2, or AUC) were observed when they were administered 400 mg of lomefloxacin as a single dose. No data are available in cirrhotic patients treated with multiple doses of lomefloxacin. Cirrhosis does not appear to reduce the nonrenal clearance of lomefloxacin. There does not appear to be a need for a dosage reduction in cirrhotic patients, provided adequate renal function is present.</p><p><strong>Metabolism and pharmacodynamics of lomefloxacin</strong></p><p>Lomefloxacin is minimally metabolized although 5 metabolites have been identified in human urine. The glucuronide metabolite is found in the highest concentration and accounts for approximately 9% of the administered dose. The other 4 metabolites together account for &lt; 0.5% of the dose.</p><p>Approximately 10% of an oral dose was recovered as unchanged drug in the faeces.</p><p>Serum protein binding of lomefloxacin is approximately 10%.</p><p>The following are mean tissue- or fluid-to-plasma ratios of lomefloxacin following oral administration. Studies have not been conducted to assess the penetration of lomefloxacin into human cerebrospinal fluid.</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue or Body Fluid</strong></p></td><td style="vertical-align:top"><p><strong>Mean Tissue- or Fluid-to-Plasma Ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Bronchial secretions</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Prostatic tissue</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Sputum</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Urine</p></td><td style="vertical-align:top"><p>140.0</p></td></tr></tbody></table><p>In two studies including 74 healthy volunteers, the minimal dose of UVA light needed to cause erythema (MED-UVA) was inversely proportional to plasma lomefloxacin concentration. The MED-UVA values (16 hours and 12 hours postdose) were significantly higher than the MED-UVA values 2 hours postdose at steady state. Increasing the interval between lomefloxacin dosing and exposure to UVA light increased the amount of light energy needed for photoreaction. In a study of 27 healthy volunteers, the steady state AUC values and Cmin&nbsp;values were equivalent whether the drug was administered in the morning or in the evening.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, mutagenesis, impairment of fertility</u></p><p>Carcinogenesis</p><p>Hairless (Skh-1) mice were exposed to UVA light for 3.5 hours five times every two weeks for up to 52 weeks while concurrently being administered lomefloxacin. The lomefloxacin doses used in this study caused a phototoxic response. In mice treated with both UVA and lomefloxacin concomitantly, the time to development of skin tumors was 16 weeks. In mice treated concomitantly in this model with both UVA and other quinolones, the times to development of skin tumors ranged from 28 to 52 weeks.</p><p>Ninety-two percent (92%) of the mice treated concomitantly with both UVA and lomefloxacin developed well-differentiated squamous cell carcinomas of the skin. These squamous cell carcinomas were nonmetastatic and were endophytic in character. Two-thirds of these squamous cell carcinomas contained large central keratinous inclusion masses and were thought to arise from the vestigial hair follicles in these hairless animals.</p><p>In this model, mice treated with lomefloxacin alone did not develop skin or systemic tumors.</p><p>There are no data from similar models using pigmented mice and/or fully haired mice</p><p>The clinical significance of these findings to humans is unknown.</p><p>Mutagenesis</p><p>One in vitro mutagenicity test (CHO/HGPRT assay) was weakly positive at lomefloxacin concentrations &ge; 226 &micro;g/mL and negative at concentrations &lt; 226 &micro;g/mL. Two other in vitro mutagenicity tests (chromosomal aberrations in Chinese hamster ovary cells, chromosomal aberrations in human lymphocytes) and two in vivo mouse micronucleus mutagenicity tests were all negative.</p><p>Impairment of fertility</p><p>Lomefloxacin did not affect the fertility of male and female rats at oral doses up to 8 times the recommended human dose based on mg/m2&nbsp;(34 times the recommended human dose based on mg/kg).</p><p><strong>Animal pharmacology</strong></p><p>Lomefloxacin and other quinolones have been shown to cause arthropathy in juvenile animals. Arthropathy, involving multiple diarthrodial joints, was observed in juvenile dogs administered lomefloxacin at doses as low as 4.5 mg/kg for 7 to 8 days (0.3 times the recommended human dose based on mg/m2&nbsp;or 0.6 times the recommended human dose based on mg/kg). In juvenile rats, no changes were observed in the joints with doses up to 91 mg/kg for 7 days (2 times the recommended human dose based on mg/m2&nbsp;or 11 times the recommended human dose based on mg/kg). (See Special warnings and precautions for use).</p><p>In a 13-week oral rat study, gamma globulin decreased when lomefloxacin was administered at less than the recommended human exposure. Beta globulin decreased when lomefloxacin was administered at 0.6 to 2 times the recommended human dose based on mg/m2. The A/G ratio increased when lomefloxacin was administered at 6 to 20 times the human dose. Following a 4-week recovery period, beta globulins in the females and A/G ratios in the females returned to control values. Gamma globulin values in the females and beta and gamma globulins and A/G ratios in the males were still statistically significantly different from control values. No effects on globulins were seen in oral studies in dogs or monkeys in the limited number of specimens collected.</p><p>Twenty-seven NSAIDs, administered concomitantly with lomefloxacin, were tested for seizure induction in mice at approximately 2 times the recommended human dose based on mg/m2. At a dose of lomefloxacin equivalent to the recommended human exposure based on mg/m2&nbsp;(10 times the human dose based on mg/kg), only fenbufen, when co-administered, produced an increase in seizures.</p><p>Crystalluria and ocular toxicity, seen with some related quinolones, were not observed in any lomefloxacin-treated animals, either in studies designed to look for these effects specifically or in subchronic and chronic toxicity studies in rats, dogs, and monkeys.</p><p>Long-term, high-dose systemic use of other quinolones in experimental animals has caused lenticular opacities; however, this finding was not observed with lomefloxacin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Carboxy methyl cellulose calcium</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Hydroxypropyl cellulose</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Lactose monohydrate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Magnesium stearate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Polyoxyl 40 stearate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>De-ionized water *</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Ethanol 95% *</li></ol></td></tr><tr><td style="vertical-align:top"><p><strong><u>Coating Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Hypromellose</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Polyethylene glycol 6000</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Titanium dioxide</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Talc fine powder</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>De-ionized water *</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Ethanol 95% *</li></ol></td></tr></tbody></table><p>&nbsp;</p><p>* Evaporates during drying and coating process.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, in a dry place, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Pack of 5 Tablets:</strong> 1 x 5&rsquo;s tablets packed in Aluminium foil PVC film, plain, white opaque blister, packed in a printed carton along with a leaflet.</p><p>&sect; <strong>Pack of 10 Tablets:</strong> 1 x 10&rsquo;s tablets packed in Aluminium foil PVC film, plain, white opaque blister, packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19. November. 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>